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Abstract 
Successful pregnancy requires the coordination of several maternal systems to 
accommodate the developing fetus.  Of these, the maternal immune system must be 
carefully modulated as the fetus is immunologically foreign to her leukocytes. In 
these studies, we propose that the CD28 family of immune receptors functions during 
pregnancy to control maternal immune reactions. These receptors bind to members of 
the B7 family of co-stimulatory molecules to influence leukocyte activation, either 
negatively or positively.  One CD28 family member, PD-1, is expressed on T 
lymphocytes and following interaction with its ligand, B7-H1, prevents T cell 
activation. This pathway maintains self-tolerance and prevents allograft rejection 
through mechanisms including modulation of cytokine production, suppression of 
proliferation or apoptosis induction.  Interestingly, B7-H1 is abundantly expressed in 
the human placenta throughout gestation. Therefore we studied the role of the PD-1 
receptor in modulating maternal T cells during pregnancy. Within the human 
maternal-fetal interface, PD-1 is preferentially expressed on decidual T cells as 
compared to their counterparts in peripheral blood and B7-H1 inhibits the 
inflammatory cytokine production of activated decidual T lymphocytes.  In addition, 
through mechanisms possibly involving B7-H1:PD-1 interactions, primary human 
trophoblast cells induce a regulatory T cell phenotype that can suppress the 
proliferation of other T cells.  Finally, in murine pregnancy, PD-1 controls the 
accumulation of paternal antigen-specific T cells in the lymph nodes draining the 
uterus potentially through induction of apoptosis. Overall, the PD-1:B7-H1 pathway 
 iv 
functions at multiple sites through distinct mechanisms to help maintain maternal-
fetal tolerance for the ultimate goal of successful pregnancy and healthy fetal 
development.   
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A. The immunology of pregnancy  
1.  Successful pregnancy requires systemic coordination 
The production of offspring in viviparous species is a complex process during 
which the maternal anatomy and physiology are naturally modified to accommodate 
one or more developing fetuses for a prolonged period of time.  Intricate coordination 
of several physiological systems is required for delivery of numerous signals and 
modulation of cellular activity at precise times throughout gestation.  While these 
processes are successfully synchronized in healthy pregnancy, it is not surprising that 
commonly, one or more processes do not function correctly, thus resulting in 
infertility and gestational pathologies. Thus, the ability to conceive a child and 
maintain a successful pregnancy remains a challenge in today's society despite the 
ongoing development of therapies and clinical protocols to combat this problem.  A 
national survey on the fertility of women in America estimated that 6.1 million 
women have impaired ability to conceive and that 2.1 million couples experience 
infertility (Statistics, CDC 1997).  In addition, other studies have found that up to 
30% of patients with known pregnancies experience miscarriage (Wilcox et al. 1988; 
Everett 1997).   
In order to improve the reproductive health of women, it is essential to 
understand the biological reasons underlying these unfortunate statistics.  Among the 
systems that are required for successful pregnancy, a potential cause for infertility and 
fetal loss may involve improper regulation of the maternal immune system.  An 
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imbalance of immunological control during pregnancy can result in miscarriage, pre-
eclampsia, or impaired fetal growth (Pearson 2002).   
2. Overview of the immune system  
The immune system is comprised of an intricately connected network of cell 
populations that ultimately function to mount responses against foreign entities in the 
body, such as viral or bacterial pathogens.   Immune cell, or leukocyte, populations 
are grouped within two branches of the immune system, innate and the adaptive 
immunity.  For responses against pathogens, cells of the innate immune system 
recognize bacteria and viruses through a series of pattern recognition receptors that 
subsequently initiate rapid non-specific inflammatory responses (Takeda et al. 2003). 
Cells of this type of immunity include natural killer cells, dendritic cells and 
macrophages.  Once activated, these cells communicate with members of the adaptive 
immune system, which respond in turn by mounting more specific and longer lasting 
effector responses against pathogens; T and B lymphocytes are the main effector cells 
of the adaptive immune system.   
Communication between the innate and adaptive immune systems occurs 
through cell-cell interactions and secreted products.  Natural killer cells carry out 
direct effector mechanisms against pathogen-infected cells and produce cytokines that 
activate other immune cells. In addition, during the initial response to a pathogen, 
macrophages and dendritic cells process and present antigens to T lymphocytes of the 
adaptive immune system. Two principal types of T cells, distinguished by their 
surface expression of CD4 or CD8 molecules, possess different effector functions. 
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Depending on the nature of the pathogen, CD4+ helper T cells produce cytokines that 
fall into two broad categories. Th1 cytokines stimulate cellular immune responses and 
Th2 cytokines initiate humoral immune responses. In Th1 type (cellular) immunity, 
CD4+ helper T lymphocytes respond to antigen presentation by producing cytokines 
that activate CD8+ (cytotoxic) T cells, which, following antigen exposure, carry out 
direct effector mechanisms against pathogen-infected cells.   During Th2 (humoral) 
immune responses CD4+ T cell cytokines activate B lymphocytes, which respond to 
antigen exposure by producing epitope-specific antibodies against that antigen.  
T cells recognize self and non-self antigen only in the context of major 
histocompatability complex proteins (MHC).  These cell surface proteins have a high 
level of polymorphism, such that each individual possesses a unique repertoire.  MHC 
molecules are categorized into two classes.  Class I MHC proteins are found on the 
surface of nearly all cells in the body and present intracellular antigen to CD8+ T cells 
including peptides derived from self-proteins and intracellular pathogens.  Class II 
MHC expression is restricted to professional antigen presenting cells, such as 
macrophages, dendritic cells and endothelial cells, and these molecules present 
extracellularly derived antigens.  In contrast to Class I, Class II MHC proteins present 
antigen to CD4+ T cells.  
Presentation of peptides derived from self proteins serves the function of 
inducing tolerance to autologous tissues.  Immune tolerance is a process by which the 
T cell repertoire is specifically modified to prevent reactions against self-antigens and 
self MHC.  The ultimate goal of tolerance induction is to prevent T cell reactivity 
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against autologous tissues and the mechanism of tolerization can include death, 
anergy or even differentiation of T cells (Hugues et al. 2006; Cook et al. 2007). This 
can occur "centrally" in the thymus during T cell development or "peripherally" after 
mature T cells exit the thymus.  Central tolerance occurs through deletion of T cells 
that react inappropriately to self-antigens presented by self-MHC in the thymus. 
Peripheral tolerance occurs as a result of recognition of self antigen in regional lymph 
nodes by self-reactive T cells that have escaped tolerance induction in the thymus.  
Peripheral tolerance can also be developed against certain non-self antigens. For 
example, mesenteric lymph nodes draining the intestine are a site for induction of oral 
tolerance against ingested antigens (Kraal et al. 2006) .   
The result of central and peripheral tolerance is the absence of reactivity to 
self antigens and self MHC. Conversely, T cells mount strong cytotoxic responses 
against non-self  MHC.  This was realized through a series of experiments involving 
skin grafts in mice, in which grafts transplanted between inbred strains of mice 
containing identical MHC profiles (syngeneic) were accepted, while grafts between 
different strains with different MHC profiles (allogeneic) were rejected (Klein 1986).  
These studies led to the term “histocompatability” for MHC, as it was discovered that 
these molecules were responsible for the immune reactions being compatible with 
self, but not foreign tissue. This concept also became evident in human recipients of 
kidney transplants or blood transfusions who made antibodies against antigens on the 
surface of the donor leukocytes, which were identified as the human MHC molecules 
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and subsequently named human leukocyte antigens (HLA) (Dausset 1954; van Rood 
1993).  
 
3. The immune paradox of pregnancy 
As more understanding was gained about the involvement of MHC/HLA 
molecules in the role of graft acceptance or rejection, the phenomenon of pregnancy 
in this context came under consideration. This is an immunological paradox first 
proposed by Sir Peter Medawar (Medawar 1953) who recognized that due to the 
genetic disparity of mother and fetus, including MHC, the maternal immune system 
should reject fetal tissues.  Instead, the fetus is accepted for the duration of 
pregnancy. Medawar further postulated three explanations for the lack of semi-
allogeneic fetal rejection: an anatomical separation between mother and fetus, a non-
antigenic status of fetal tissues, and a paucity of maternal immune responses during 
pregnancy. The latter two proposed mechanisms have been supported through 
numerous studies.  However, in humans, acceptance of the fetus may not depend on 
anatomically separated fetal tissues as the placental cells intimately contact maternal 
tissues in the gravid uterus throughout gestation.  
 
4. The maternal-fetal interface 
One of the requirements of viviparous species is delivery of nutrients to the 
developing fetus throughout gestation.  Humans accomplish this goal through 
hemochorial placentation in which the fetal placenta is attached to the uterus and is 
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constantly bathed in maternal blood supplied by the uterine arteries throughout 
gestation. Figure 1.1 illustrates various components of this interface between maternal 
and fetal tissues.  The human placenta is comprised of a network of branching villi 
containing a core of fetal blood vessels originating from the umbilical artery and 
veins.  These villous blood vessels are covered by two layers of specialized 
phagocytic cells called trophoblasts (Fig. 1.1 B). The inner trophoblast layer consists 
of villous cytotrophoblast cells that differentiate and fuse to form syncytiotrophoblast 
cells constituting the outer layer. These cells take up molecules from the maternal 
blood and transfer them to the blood vessels within the core of the villi, thus 
transferring maternal nutrients to fetus throughout gestation.  In addition, upon their 
differentiation, syncytiotrophoblast cells acquire an endocrine function, producing 
several steroid and peptide hormones critical for the maintenance of pregnancy 
(Kaufmann 1982).  Trophoblast cells also comprise the chorion membrane, one of the 
layers constituting the extraplacental membranes surrounding the fetus (Fig. 1.1 C). 
These extraplacental membranes encase the amniotic fluid in which the fetus 
develops.  
Throughout gestation, the placenta and fetal membranes are in contact with 
maternal decidua, specialized uterine tissue, which is divided into anatomical regions 
within the gravid uterus.  The decidua basalis juxtaposes the placenta, decidua 
capsularis surrounds the fetal membranes, and decidua parietalis is located on the 
opposite side of the fetus from the attachment site of the placenta (Fig. 1.1).  As the 
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fetus grows larger and its associated membranes expand throughout pregnancy, the 
decidua capsularis and parietalis fuse to become one entity (Benirschke et al. 2000). 
Within the decidua basalis an additional trophoblast cell type is located. At the 
points of attachment to the decidua basalis, cytotrophoblasts migrate out from the villi 
to become extravillous trophoblast cells, initially proliferating to form cell columns 
and then migrating deeper into decidual tissue. Some extravillous trophoblasts invade 
maternal uterine spiral arteries, transforming them into low resistance vessels 
allowing increased blood flow to placental tissues (Fig. 1.1 A).    The transformation 
of spiral arteries ensures increased nutrient delivery to the placenta in elegant 
congruence with augmented fetal growth as gestation progresses (Harris et al. 2007).  
Similar to human pregnancy, mice utilize hemochorial placentation to support 
their developing fetuses in utero.  Trophoblast cells within the murine placenta also 
have access to maternal blood and uterine tissues, thus maintaining intimate contact 
between mother and fetus (Georgiades et al. 2002).   Mice are therefore commonly 
used as a model to study maternal responses to fetal antigen during pregnancy 
(Vacchio et al. 1999; Erlebacher et al. 2007).   
 
5. Decidual leukocytes 
Due to the immunological discrepancy between mother and fetus, the gravid 
uterus was initially thought to be an immune privileged site, as is observed for other 
parts of the body, such as the eye, gonads and central nervous system (Simpson 
2006). However, several inaugural studies showed that the human maternal-fetal 
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interface contains multiple populations of leukocytes, from both innate and adaptive 
branches of the immune system (Fig. 1.1).  These cells remain active within the 
gravid uterus, as they are capable of mounting responses against invading pathogens 
and commonly, their activity is also directed toward physiological functions during 
pregnancy.    
 
i. NK cells 
Natural killer (NK) cells of the innate immune system are the most abundant 
population in the gravid uterus within early pregnancy, and decrease in number as 
gestation continues. Decidual NK (dNK) have a CD16- CD56bright surface phenotype 
and are less cytotoxic than peripheral blood CD16+ CD56dim NK. The main function 
of dNK at the maternal-fetal interface appears to be production of cytokines and 
chemokines that can potentiate trophoblast invasiveness and angiogenesis (Hanna et 
al. 2006; Hanna et al. 2007).   Because of this function, dNK play a critical role in 
decidual artery remodeling during pregnancy as shown through in vivo dNK deficient 
mouse models (Guimond et al. 1997; Ashkar et al. 2000).  
 
ii. Macrophages 
 Macrophages comprise around 18-25% of decidual leukocytes and remain in 
relatively constant numbers throughout gestation (Vince et al. 1990).   Decidual 
macrophages (dMΦ) express lower levels of MHC-II and the co-receptor CD86 than 
peripheral blood monocytes of pregnant and non-pregnant women (Heikkinen et al. 
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2003). This surface phenotype suggests that dMΦ may be less efficient at presenting 
antigen and indeed dMΦ may have a decreased capacity to induce T cell responses in 
comparison with their peripheral blood counterparts (Hunt et al. 1992; Mizuno et al. 
1994).  The reduced stimulatory capacity of dMΦ could also be attributed to their 
production of anti-inflammatory cytokines such as IL-10 (Hunt 1994; Heikkinen et al. 
2003).   In addition, these cells may prevent inflammation at the maternal-fetal 
interface through phagocytosis of apoptotic trophoblast cells; the dead cells would 
thus be prevented from releasing their contents, which could stimulate anti-fetal 
responses (Mor et al. 2006).  
 
iii. Dendritic cells 
Dendritic cells are an additional antigen presenting cell in the decidua. 
Broadly, the functional outcome of interactions between a dendritic cell and a naïve T 
cell is determined by the activation state of the dendritic cell at the time of interaction.  
For example, presentation of an antigen by activated or mature dendritic cells can 
result in T cell priming and induction of an immune response to the corresponding 
antigen, while presentation of the same antigen by immature, or steady-state dendritic 
cells can induce antigen-specific T cell tolerance (Steinman et al. 2003).   During 
pregnancy decidual dendritic cells express markers consistent with an immature 
phenotype (Kammerer et al. 2000; Gardner et al. 2003; Rieger et al. 2004). Thus, they 
may be readily available to help promote tolerance of the fetal allograft either within 
the maternal-fetal interface or in the uterine draining lymph nodes.    
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iv. T  lymphocytes 
Because T lymphocytes have a central role in graft rejection (Rocha et al. 
2003), the interaction of fetal antigen and maternal T lymphocytes was initially 
thought to be a route for rejection of the semi-allogeneic fetus.  However, maternal T 
cells are among the main immune cell populations at the human maternal-fetal 
interface, constituting 15-30% of decidual leukocytes in first trimester (Morii et al. 
1993; Mincheva-Nilsson et al. 1994; Vassiliadou et al. 1996), and are present in 
constant or possibly enriched percentages among decidual leukocytes at term (Haller 
et al. 1993; Sindram-Trujillo et al. 2004). Both CD4+ T helper cells and CD8+ 
cytotoxic T cells are found in equal abundance relative to total CD3+ T cell 
population within the decidua (Vassiliadou et al. 1996).  
T lymphocytes at the maternal-fetal interface are not entirely quiescent as 
some express activation markers CD69 and CD25 (Chao et al. 1999; Aluvihare et al. 
2004; Tilburgs et al. 2006).   Although their functional role is unclear, they are 
apparently programmed to perform physiological functions. For example, in vitro 
stimulated decidual T cell produce cytokines that can potentiate the invasive 
capabilities of trophoblast cells (Scaife et al. 2006).  In addition CD4+CD25+ cells 
play an immunosuppressive role in pregnancy (Saito et al. 2005).   
 
6. Immunomodulation at the maternal-fetal interface 
 12 
During pregnancy, the maternal immune system is controlled through an 
intiricate network of mechanisms participating in two different types of immune 
suppression.  Within the maternal-fetal interface, there is modulation of ongoing 
immune activity without compromising the ability to mount responses against 
infectious pathogens.  Within the spleen and uterus-draining lymph nodes, these 
mechanisms control fetal-antigen specific responses, i.e. induce tolerance.  
 
i. MHC expression  
A highly studied immune evasive mechanism at the maternal-fetal interface is 
the paucity of MHC expression within the placenta.   In the human maternal-fetal 
interface, the majority of trophoblast cells lack the highly polymorphic MHC Class Ia 
HLA-A, HLA-B and Class II molecules (Petroff 2005a).  Overall, the paucity of 
MHC expression prevents maternal T cell detection of fetal histo-incompatability, 
ensuring that trophoblast cells do not serve as direct targets for anti-fetal responses. 
However, the class Ia HLA-C molecule is expressed by extravillous trophoblast cells 
(King et al. 2000), but rather than stimulating anti-fetal immune responses, this 
molecule may be involved in modulating NK cell activity (Hiby et al. 2004).   In 
addition, extravillous trophoblast cells express MHC Class Ib molecules, HLA-E, F 
and G (Ishitani et al. 2003).  Class Ib molecules are less polymorphic than those of 
the class Ia family and do not stimulate induce maternal anti-fetal immune reactions.  
HLA-G in particular has well-characterized immunosuppressive capabilities, 
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including modification of macrophage and T cell cytokine production in vitro (Kanai 
et al. 2001; McIntire et al. 2004).  
 
ii. Complement regulatory proteins 
 The complement system is an immune defense mechanism consisting of 
serum proteins that trigger direct cytotoxicity against target cells through introduction 
of membrane pores and subsequent cell lysis.   Self-tissues are protected from this 
attack by expression of complement regulatory proteins that control various 
components of the complement cascade.  Trophoblast cells are no exception (Holmes 
et al. 1990; Hsi et al. 1991), and indeed these proteins are indispensable for fetal 
survival.  Murine embryos lacking the compliment regulatory protein Crry die at mid-
gestation due to deposition of maternal compliment (Xu et al. 2000).  However, 
complement-mediated fetal loss occurs in syngeneic pregnancy suggesting that these 
regulatory proteins provide homeostatic rather than allo-antigen-specific suppression.   
  
iii. The Fas/Fas ligand proteins 
 Fas is member of the TNFR family, can be highly expressed by activated T 
cells (Drappa et al. 1993), and upon binding of its ligand (FasL) is known to induce 
peripheral T cell apoptosis (Singer et al. 1994).  Fas-L-expressing human trophoblast 
cells can be found in close proximity to apoptotic decidual leukocytes in situ, and 
primary trophoblast cells can induce Fas-L-mediated apoptosis of activated 
lymphocytes in vitro (Mor et al. 1998; Coumans et al. 1999).   In murine pregnancy, 
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fetal FasL may responsible for deletion of fetal antigen-specific T cells during late 
gestation (Vacchio et al. 2005),  although interruption of this pathway during 
pregnancy did not cause fetal rejection even when maternal T cell responses are 
skewed toward responsiveness major or minor paternal antigens (Rogers et al. 1998; 
Vacchio et al. 2005).  
 
iv. Indoleamine-2,3 dioxygenase 
Indoleamine-2,3-dioxygenase (IDO) is a tryptyphan-catabolizing enzyme that 
may be involved in the maintenance of  T cell tolerance (Mellor et al. 2004). While 
short-term pharmacological inhibition of IDO resulted in T cell mediated rejection of 
allogenic fetuses (Munn et al. 1998), genetic deletion of IDO did not result in 
corresponding fetal rejection (Baban et al. 2004).  These studies suggest an inability 
to prevent maternal T cell responses with the acute loss of IDO while redundant 
mechanisms may be protecting the fetus during a long-term absence of this molecule.  
 
v. Cytokines 
Early examination of cytokines in pregnancy proposed a “Th-2 bias” in which 
anti-inflamamatory Th2 cytokines are preferentially produced over pro-inflammatory 
Th1 cytokines to maintain maternal immunological suppression (Wegmann et al. 
1993). Indeed, overproduction of Th1or paucity of Th2 cytokines is associated with 
recurrent spontaneous abortion in humans and fetal loss in mice (Piccinni et al. 1998; 
El-Shazly et al. 2004; Mjihdi et al. 2004; Kim et al. 2005; Murphy et al. 2005).  
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However, inflammatory cytokines may also control trophoblast invasion in early 
pregnancy, and play a role in parturition at term (Pollard et al. 1993; Buonocore et al. 
1995; Ashkar et al. 2000; Fukushima et al. 2003; Cohen et al. 2006; Scaife et al. 
2006). Thus both Th1 and Th2 cytokines are important during pregnancy, and it 
appears that a balance Th1/Th2 production is critical in promoting maternal immune 
tolerance to the fetus while allowing leukocytes to perform physiological functions 
within the maternal-fetal interface (Wilczynski 2005).  
 
vi. Regulatory  T  cells 
Among the several mechanisms proposed to maintain T cell tolerance in 
pregnancy, one of the most experimentally robust mechanisms identified to date 
involves the suppressive activity of CD4+CD25+FoxP3+ regulatory T cells (Treg).  
These cells suppress the activation and proliferation of autologous T cells primarily 
through contact-dependent mechanisms (Thornton et al. 1998; Sasaki et al. 2004) and 
are key regulators of autoimmune T cell reactivity (Sakaguchi 2000; Shevach 2002). 
Treg expand in the peripheral blood and lymph organs of both pregnant women and 
mice, and preferentially localize to the decidua (Aluvihare et al. 2004; Heikkinen et 
al. 2004; Sasaki et al. 2004; Somerset et al. 2004; Tilburgs et al. 2006).   Further, they 
are required for the survival of semi-allogeneic fetuses during murine pregnancy 
models (Aluvihare et al. 2004; Zenclussen et al. 2005; Darrasse-Jeze et al. 2006) and 
associated with healthy pregnancy humans (Sasaki et al. 2004).  This expansion of 
and functional requirement for Treg highlights the importance of proper 
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immunological control of maternal T cells during pregnancy, and suggests that 
mechanisms involved in maintaining self-tolerance may also be utilized to establish 
maternal-fetal tolerance.   
 
B. The B7 and CD28 families 
Another well-established mechanism for modulating T lymphocyte function 
and maintaining tolerance to self-antigens involves the B7 and CD28 families of 
immune cell co-receptors (Greenwald et al. 2005).  B7 molecules bind to members of 
the CD28 receptor family to influence lymphocyte activation, either negatively or 
positively (Greenwald et al. 2005) (Fig. 2).  Both the B7 and CD28 families are type I 
transmembrane proteins classified within the immunoglobulin superfamily.   The first 
members of the B7 family to be characterized, B7-1 and B7-2, are expressed 
primarily by antigen presenting cells, i.e. macrophages and dendritic cells (Freedman 
et al. 1987; Freeman et al. 1991; Freeman 1993; Freeman et al. 1993).  Both B7-1 and 
B7-2 bind to CD28, a receptor that is constitutively expressed on T cells (Aruffo et al. 
1987; Gross et al. 1990) (Fig. 1.2), the ligation of which is required for optimal T cell 
activation (Jenkins et al. 1991; Shahinian et al. 1993).   Without this signal from 
CD28, the T cells either die or become anergic.  Indeed, the delivery of the MHC 
signal in the absence of CD28 ligation has been postulated to serve as a mechanism of 
tolerance (Bretscher 1999).   B7-1 and B7-2 also ligate another receptor, CTLA-4, 
which is present only on activated T cells and plays an important role in down-
regulation of an ongoing immune response (Brunet et al. 1987) (Fig. 1.2). 
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Since the initial characterization of these proteins, five additional B7 proteins 
and two CD28 family receptors have been identified (Fig. 1.2).  Like the function of 
B7-1 and B7-2, most novel B7 family members can either stimulate or inhibit the 
immune cells with which they interact, depending on the receptor they bind 
(Greenwald et al. 2005).  With regard to pregnancy, the B7 family members B7-2, 
B7-H1, B7-DC, B7-H2, and B7-H3 have been mapped at the human maternal-fetal 
interface (Petroff et al. 2003; Petroff et al. 2005b).   
 
C. The B7-H1:PD-1 pathway 
1. B7-H1: a uniquely expressed B7 family member 
B7-H1 was the third B7 family member to be characterized.  Unlike B7-1 and 
B7-2, B7-H1 can be expressed by both immune and non-immune cells.  B7-H1 is 
found on macrophages, dendritic cells and activated lymphocytes (Liang et al. 2003); 
outside of the immune system, B7-H1 is expressed by activated endothelial cells but 
is only found on the parenchymal cells of organs under inflammatory conditions (Iwai 
et al. 2003; Liang et al. 2003).   One major exception is human trophoblast cells, 
which constituitively express B7-H1 throughout pregnancy (Petroff et al. 2003; 
Petroff et al. 2005b).   Consistent with this finding, the placenta contains higher levels 
of B7-H1 mRNA when compared to other non-immune organs (Dong et al. 1999).  
These data suggest a unique requirement for and specific regulation of B7-H1 
expression at the maternal-fetal interface.    
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During pregnancy, B7-H1 expression is low in first trimester and increases in 
term placental tissues. B7-H1 is correspondingly downregulated in vitro by low 
oxygen tension similar to that observed in early pregnancy (Holets et al. 2006). B7-
H1 expression can also be increased by post-translational mechanisms through 
treatment with epidermal growth factor (EGF), which causes trophoblast 
differentiation (Petroff et al. 2003). Through regulation by EGF and oxygen, B7-H1 
expression is increased as the placenta matures and increased nutrients are delivered 
to the fetus, which may be a critical period for immunomodulation within the 
maternal-fetal interface.   
While B7-H1 has been well mapped in human pregnancy, its location at the 
murine maternal-fetal interface remains unclear (Liang et al. 2003; Guleria et al. 
2005).   B7-H1 mRNA is present in both decidua and placenta (Taglauer and Petroff, 
unpublished data).  However, conflicting reports suggest protein expression on 
maternal decidual cells or trophoblast cells (Liang et al. 2003; Guleria et al. 2005).  
 
2. PD-1: the inhibitory receptor for B7-H1 
PD-1 is the receptor for B7-H1 as well as for another B7 family member, B7-
DC (Freeman 2000; Latchman et al. 2001) (Fig. 1.2).  PD-1 was first identified in T 
cells undergoing apoptosis and has since been identified on activated T, B, and 
myeloid cells (Ishida et al. 1992; Agata et al. 1996).  The cytoplasmic domain of PD-
1 contains two tyrosines that are associated with different intracellular signaling 
motifs.  One is within an intracellular tyrosine inhibitory motif (ITIM), which can 
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mediate immunoreceptor inhibitory functions (Ishida et al. 1992).  The other tyrosine 
is within an intracellular tyrosine switch motif (ITSM), which can bind either tyrosine 
or inositol phosphatases to result in different outcomes of receptor signaling 
(Shlapatska et al. 2001).    Studies involving PD-1 chimeric proteins demonstrate that 
when the PD-1 cytoplasmic domain is activated through antigen stimulation, the 
ITSM in PD-1 recruits the SHP-2 tyrosine phosphatase.  Recruitment of SHP-2 can 
cause inhibition of lymphocyte activation by de-phosphorylating proteins in the 
antigen receptor signalling (Okazaki 2001; Chemnitz et al. 2004; Paul A. Saunders 
2005). SHP-2 activity ultimately leads to deactivation of signaling molecules 
including phosphatidylinositol-3 kinase (PI3K), phospholipase C-(PLC) γ2,  and 
external signal-regulated kinase (ERK), all of which are involved in signal 
transduction pathways carry out diverse functions of cell survival, proliferation, and 
differentiation of lymphocytes (Okazaki 2001).      
 
3. Effects of B7-H1: PD-1 interactions at the cellular level  
The effects of B7-H1 and PD-1 interactions were initially studied using in 
vitro culture systems.  In these studies, B7-H1 was found to inhibit the T cell cytokine 
secretion and proliferaion (Freeman 2000; Latchman et al. 2001).  Further studies also 
suggested that B7-H1:PD-1 interactions can also result in apoptosis (Dong et al. 
2002; Hori et al. 2006; Muhlbauer et al. 2006).  Both CD4+ and CD8+ T cell subsets 
are susceptible to B7-H1 inhibition, although CD8+ may be more sensitive to B7-H1 
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(Carter et al. 2002).  However other studies have revealed that B7-H1 may 
preferentially suppress CD4+ T cells during allograft responses (Ito et al. 2005) 
Treg also utilize the B7-H1:PD-1 pathway to differentiate or to inhibit of 
autologous T lymphocyte activation.  These cells can express B7-H1, which may 
mediate Treg suppression of effector CD4+ T cells (Yang et al. 2006; Jinushi et al. 
2007).  PD-1 has also been identified on Treg (Jinushi et al. 2007) and two recent 
studies have suggested that B7-H1 signaling may induce the differentiation of  these 
cells outside of the thymus (Krupnick et al. 2005; Beswick et al. 2007).  
Other studies have suggested that B7-H1 can also stimulate lymphocytes.  
Under different in vitro conditions, B7-H1 may cause increases in T cell proliferation 
and secretion of interleukin-10, an anti-inflammatory cytokine (Dong et al. 1999).  
Interestingly, in mutated B7-H1 proteins with disrupted PD-1 binding ability, 
stimulatory effects were still observed, suggesting that B7-H1 may work through a 
different receptor to cause stimulation (Wang et al. 2003). However, this receptor has 
not yet been identified.   
 
D. Pathological and physiological consequences of B7-H1: PD-1 interactions  
The characterization of B7-H1 interactions through PD-1 and the implications 
of this interaction as a negative regulator of lymphocytes began to draw attention 
from several areas of research.  Roles for B7-H1 and PD-1 have been identified in 
cancer, infectious disease, autoimmunity, transplantation, and reproduction. 
Depending on the context, the presence of B7-H1 or PD-1 may have a pathological 
 21 
role, as in cancer or infectious disease, or a physiologic role, as in self-tolerance, 
allograft-acceptance and pregnancy.   
 
1. Tumor biology 
Although it is not normally expressed on parenchymal cells of organs, B7-H1 
is constitutively expressed on several tumors of different origin (Dong et al. 2002; 
Brown et al. 2003; Thompson et al. 2004). In mouse studies, B7-H1 expression on 
mastocytoma tumor cells can cause apoptosis of tumor-specific T cells (Dong et al. 
2002). In addition, the growth of B7-H1-expressing myeloma cells are completely 
suppressed in PD-1 deficient mice (Iwai et al. 2002). Interestingly, in human clinical 
studies, the presence of B7-H1 on renal cell carcinomas correlates with aggressive 
tumors and poor long-term prognosis, also implying that B7-H1 is inhibiting host 
anti-tumor immune defenses (Thompson et al. 2004; Thompson et al. 2006). Tumors 
can also evade the immune system through induction of regulatory T cells that could 
suppress anti-tumor T cell reactions.  Interestingly, B7-H1 is expressed by Treg 
infiltrating into B-cell hodgekins lymphomas, and may mediate Treg suppression of 
intratumoral T cell proliferation (Yang et al. 2006). Overall, these data suggest that 
the B7-H1:PD-1 pathway can serve as a mechanism for tumors to escape host 
immune responses 
2. Infectious disease 
Induction of B7-H1 on antigen presenting cells may also result in decreased 
immune responses against pathogens.  During a parasitic infection, macrophages from 
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Schistosoma mansoni-infected mice have elevated B7-H1 expression levels and 
through B7-H1, induce anergy in T cells (Smith et al. 2004). In addition, intestinal 
epithelial cells infected with Helicobacter Pylori bacteria also upregulate B7-H1 
following infection. In this model, B7-H1 induced differentiation of Treg that could 
suppress anti-bacterial T cell responses (Beswick et al. 2007).  Other studies have 
also focused on the role of PD-1 on T cells in infectious disease. In mice, during 
chronic lymphocytic choriomeningitis virus (LCMV) infection, CD8+ T cells are 
inhibited through PD-1, culminating in failure of viral clearance (Barber et al. 2006).  
Consistent with this idea, PD-1-null, adenovirus-infected mice have increased 
effector T cell proliferation and accelerated viral clearance suggesting the absence of 
PD-1 may aid in overcoming a viral infection (Iwai et al. 2003).   
  
3. Autoimmune disease 
Although expression of B7-H1 and PD-1 in tumors and infectious diseases 
may have a pathological influence, there are clearly also physiologic roles for these 
proteins.  For example PD-1 and B7-H1 have a central role in preventing autoimmune 
reactions.  PD-1 knockout mice develop autoimmune phenotypes that depend on the 
background strain of mouse.  C57BL/6 PD-1-/- mice develop late-onset, lupus-like 
arthritis and glomerulonephritis (Nishimura et al. 1999), while BALB/c PD-1-/- mice 
develop severe early-onset dilated cardiomyopathy characterized by autoreactive 
antibodies against cardiac troponin-1 (Nishimura et al. 2001; Nishimura et al. 2003). 
The consequences of genetic alteration of PD-1 are also evident in humans where 
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small nucleotide polymorphisms (SNPs) in the PD-1 gene may be associated with 
certain autoimmune diseases including systemic lupus erythemous and type I diabetes 
(Prokunina et al. 2002; Nielsen et al. 2003; Ni et al. 2007).  In more recent studies, 
models utilizing antigen specific T cells demonstrate that PD-1 is involved the 
induction of self reactive T cell anergy in the periphery (Tsushima et al. 2007), and 
this inhibitory receptor prevents antigen-specific cytotoxic T cell attack of self-tissues 
(Martin-Orozco et al. 2006; Keir et al. 2007).   Overall these combined results suggest 
that PD-1 has a critical role in maintaining tolerance of immune cells to self-antigens 
in peripheral organs.   
Unlike PD-1 knockout mice, B7-H1-deficient mice do not spontaneously 
develop autoimmune disease.  However, in vitro, CD8+ T cells from B7-H1-/- mice 
display increased antigen-specific cytotoxic responses when compared to wildtype 
controls.  In vivo, B7-H1 knockout mice are more susceptible to experimental 
autoimmune hepatitis and encephalomyelitis, and diabetes that wild type controls 
(Dong et al. 2004; Latchman et al. 2004; Keir et al. 2006).  
 
4. Allograft tolerance 
In addition to preventing autoimmune disease, B7-H1 and PD-1 function to 
suppress allograft rejection.  In allogeneic murine cardiac transplants, B7-H1 and PD-
1 are expressed on recipient leukocytes infiltrating the cardiac tissue during rejection 
(Ozkaynak et al. 2002). This pathway can work either independently or 
synergistically with other immunosuppressive agents to promote allograft survival 
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through mechanisms including control of inflammatory cytokine production and Treg 
cell induction (Ozkaynak et al. 2002; Gao 2003; Tanaka et al. 2007; Wang et al. 
2007).  Interestingly, B7-H1 expression on donor cardiac allograft tissues may also be 
critical for preventing rejection (Yang et al. 2008). This is a particularly interesting 
result because it demonstrates that B7-H1 expressed on non-immune cells can inhibit 
T cell activation against an allograft, a situation that may be analogous to trophoblast-
mediated inhibition of maternal T cells.  
 
5. Pregnancy 
In our studies, we hypothesize that the function of B7-H1 and PD-1 in 
pregnancy correlates with results from other fields: the B7-H1:PD-1 pathway may 
control immune reactions against fetal antigen.  This follows directly from 
observations that B7-H1 is highly expressed on several fetal trophoblast cells 
throughout gestation, including those invading the uterus and those that are exposed 
to maternal blood (Petroff et al. 2003; Petroff et al. 2005b).  
However, antibody-mediated blockade of maternal B7-H1 in allogeneic but 
not syngeneic pregnancy resulted in increased fetal resorption which could be 
reversed through maternal T cell depletion or transfer of B7-H1 expressing regulatory 
T cells (Guleria et al. 2005; Habicht et al. 2007).  B7-H1-/- female mice also had 
reduced litter size when bred allogeneically (Guleria et al. 2005).  These studies 
suggest that B7-H1 prevents rejection of semi-allogeneic fetuses by controlling 
maternal T lymphocyte activation.   
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E. Summary and experimental goals   
The inhibitory actions of the B7-H1:PD-1 pathway from the research areas 
described above have a common theme: various cell types express B7-H1 which then 
binds to PD-1 on immune cells and results in reduced activation or tolerance.   These 
interactions may contribute to the pathogenesis of tumors and infectious diseases, but 
also prevent autoimmune disease and promote transplant acceptance.  Due to the 
immunoinhibitory actions of PD-1, as well as the abundance and function of its 
ligand, B7-H1, at the maternal-fetal interface we hypothesize that this receptor also 
has an important role in the immunological maintenance of pregnancy.   We explored 
this hypothesis using three series of experiments.   
First, we examined the expression and function of the PD-1 receptor in human 
pregnancy.  We collected autologous peripheral blood and decidual tissues from 
patients at term pregnancy and evaluated PD-1 expression on their T cell 
subpopulations through flow cytometry. An in vitro co-culture system was developed 
to examine the effects of B7-H1 on cytokine production and cell death in decidual T 
cells.  Within this model, we evaluated suppression of previously activated T cells, 
which models suppression of ongoing immune activation of these decidual 
leukocytes.  
Second, we examined Treg during human pregnancy.  First, we analyzed their 
distribution within the peripheral blood and decidual tissues at term pregnancy. We 
also asked whether Treg may be expanded during pregnancy by factors within the 
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maternal-fetal interface.  In particular we examined whether primary trophoblast cells 
can induce a Treg phenotype from peripheral blood naïve CD4+ T cells.  
Third, we performed murine studies to examine PD-1 regulation of maternal T 
cells in vivo.  We utilized an adoptive transfer model to evaluate the role of PD-1 on 
paternal-antigen specific T cells during pregnancy, evaluating immunomodulation 
against antigen-targeted responses within the maternal lymph node and spleen. In 
addition we determined whether maternal PD-1 is required for acceptance of the 
semi-allogeneic fetus.  
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Figure 1.1. The maternal-fetal interface. Diagram of the developing human fetus 
and placenta within the gravid uterus  (A) Anchoring placental villous attaching to the 
decidua basalis.  Cytotrophoblasts migrate out from the villous to become extravillous 
trophoblast cells that reside in the decidua basalis or invade maternal uterine spiral 
arteries. (B) Placental villi lined with cytotrophoblast (CTB) and syncytiotrophoblast 
(sTB) layers facing the maternal blood space.  (C) Extraplacental membranes 
comprised in part of tropholbast cells in the chorion membrane covered with decidua 
capsularis.   
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Figure 1.2. The B7 and CD28 Families 
Schematic diagram of B7 and CD28 family members and the functional outcomes of 
cognate receptor:ligand interactions. Both the families are type I transmembrane 
proteins classified within the immunoglobulin superfamily.  B7 family ligands bind to 
CD28 family receptors on lymphocytes to influence their activation, either negatively 
(black arrows) or positively (red arrows).  
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A. Abstract  
The failure to reject the semiallogenic fetus by maternal T lymphocytes 
suggests that potent mechanisms regulate these cells. PD-1 is a CD28 family receptor 
expressed by T cells, and its ligand B7-H1 is strongly expressed by trophoblast cells 
of the human placenta. In this study, we examined whether human maternal T cells 
express PD-1. Immunofluorescence examination of uterine tissues revealed PD-1 
expression on CD3+ cells was low in non-pregnant endometrium but increased in first 
trimester decidua and remained elevated in term decidua (P < 0.05).  In addition, 
higher relative proportions of term decidual CD8bright, CD4+, and regulatory T cells 
expressed PD-1 in comparison to autologous peripheral blood (P  < 0.05).  Term 
decidual T cells also expressed full length and soluble PD-1 mRNA isoforms more 
abundantly than their peripheral blood counterparts (P ≤ 0.05). We then examined the 
effects of PD-1:B7-H1 interactions in decidual T cells.  Jar choriocarcinoma cells 
were transfected with B7-H1 and co-cultured with activated decidual CD4+ or 
CD8bright T cells for 72 hours followed by analysis of supernatant cytokine 
concentration and decidual T cell apoptosis.  As compared to empty vector 
transfected cells, B7-H1-transfected Jar cells caused a significant suppression of IFN-
γ and TNF-α production by CD4+ (P < 0.05) but not CD8bright T cells, while B7-H1 
had no effect on secretion of IL-10 or T cell apoptosis. These results suggest that the 
PD-1:B7-H1 pathway functions in modification of the maternal immune system 
during pregnancy.   
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B. Introduction 
The fetus expresses both maternal and paternal genes, and is therefore 
partially foreign, or semi-allogenic, in relation to the mother’s immune system.  
Because a central feature of the immune system is to discriminate between self and 
non-self tissues, it is paradoxical that the semi-allogenic fetus develops in the mother 
without normally being rejected by her leukocytes. Maternal T cells are among the 
main immune cell populations at the maternal-fetal interface constituting 15-30% of 
decidual leukocytes in first trimester (Morii et al. 1993; Mincheva-Nilsson et al. 
1994; Vassiliadou et al. 1996), and are present in constant or possibly enriched 
numbers at term (Haller et al. 1993; Sindram-Trujillo et al. 2004). Because their 
presence in the decidua puts them in contact with the semi-allogenic trophoblast cells 
throughout gestation, it has been thought that maternal T cell activity, including 
cytokine production, is modulated in order to maintain normal pregnancy.  
The production and activity of cytokines throughout pregnancy can result in 
either harmful or beneficial outcomes and thus need to be carefully controlled.  For 
example, an overproduction of interferon (IFN)-γ and tumor necosis factor (TNF)-α 
may be associated with recurrent spontaneous abortions in humans and fetal loss in 
mice (Jenkins et al. 2000; Mjihdi et al. 2004; Kim et al. 2005).  However, these same 
cytokines are found in normal decidual and placental tissues, and accumulating 
evidence suggests physiological roles for these factors in regulating trophoblast 
invasion, spiral artery modification and placental morphogenesis (Cohen et al. 2006; 
Scaife et al. 2006; Hanna et al. 2007). While decidual natural killer cells contribute 
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significantly to the cytokine environment at the maternal-fetal interface (Hanna et al. 
2007), decidual T cell cytokine production may also be involved in the normal 
functions of pregnancy (Scaife et al. 2006). However, because of their central role in 
allograft rejection (Rocha et al. 2003), maternal T cell activation and cytokine 
production are likely to be held in balance to promote physiological function and 
prevent pathological consequences in order to maintain healthy pregnancy.   
One mechanism by which maternal T cells may be controlled is through the 
CD28 family of immune cell co-receptors.  These cell-surface proteins transduce 
either positive or negative signals following ligation of their B7-family ligands.  One 
of these receptors, programmed cell death-1 (PD-1) is induced on activated 
lymphocytes and negatively regulates T cells through its ligand B7-H1 (also called 
PD-L1 or CD274) (Ishida et al. 1992; Agata et al. 1996; Freeman et al. 2000; 
Latchman et al. 2001; Latchman et al. 2004).   The suppressive action of PD-1 is also 
demonstrated though in vivo studies where targeted mutation or blockade of PD-1 
results in development of spontaneous tissue-specific autoimmune disease (Nishimura 
et al. 1999; Nishimura et al. 2001) or antigen specific T cell cytotoxicity against 
peripheral self-tissues (Martin-Orozco et al. 2006; Keir et al. 2007).  In addition, this 
inhibitory receptor promotes allograft acceptance (Ozkaynak et al. 2002; Tanaka et al. 
2007; Wang et al. 2007; Yang et al. 2008).   PD-1 thus appears to have a key role in 
maintaining not only immunological self-tolerance to peripheral tissues, but also 
tolerance to foreign grafts. In addition, five alternatively spliced isoforms of the PD-1 
mRNA transcript have recently been identified (Nielsen et al. 2005), including an 
 36 
isoform (PD-1 Δ Ex3) that lacks a transmembrane domain while retaining an intact 
B7-H1 binding domain, suggesting that it is a secreted but inactive form of PD-1.  
Soluble PD-1 has been detected in the synovial fluid and plasma of patients with 
rheumatoid arthritis and may act as a decoy receptor to prevent B7-H1:PD-1-
mediated T cell inhibition (Wan et al. 2006).     
Interestingly, trophoblast cells abundantly and constitutively express the PD-1 
ligand, B7-H1, throughout pregnancy including those invading the pregnant uterus 
and those exposed to maternal blood (Petroff et al. 2003; Petroff et al. 2005b).  In 
addition, B7-H1 has been suggested to be necessary for the survival of semi-allogenic 
fetuses in murine pregnancy (Guleria et al. 2005).  The role of PD-1 on T cells in 
peripheral tolerance and allograft acceptance, together with the abundance of B7-H1 
at the maternal-fetal interface suggest an important function for this receptor:ligand 
complex in the immunological maintenance of pregnancy.  The goal of this study was 
to examine the expression of the PD-1 receptor and its soluble isoforms on T cells at 
the maternal-fetal interface. In addition, we examined the effect of the PD-1:B7-H1 
interactions on maternal T cell subpopulations during pregnancy.    
 
C. Materials and methods 
Tissue collection 
All tissue samples were collected in accordance with human subjects 
protocols approved by the University of Kansas Medical Center Institutional 
Research Board (HSC #3037).  Archival mid- (n=1) and late (n=5) secretory phase 
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endometrial tissues were obtained from the University of Kansas Medical Center 
tissue bank and staged by a board-certified pathologist.   Late secretory phase 
endometrial samples were identified by pre-decidual changes and variable apical 
vacuolation of glandular epithelium, characteristic of the time at which implantation 
occurs.  Samples were collected from pre-menopausal women ages 24-49 undergoing 
surgery for reasons other than uterine pathology; patients were negative for birth 
control or replacement hormone therapies at the time of biopsy, although intrauterine 
device status was unknown.  First trimester tissues, including decidua from voluntary 
pregnancy terminations and peripheral blood, were collected from patients at 6-11 
weeks of gestation.  First trimester decidual samples were collected within the Tissue 
Collection Core (HD049480) at the University of Chicago.  Four out of seven first 
trimester decidual samples contained decidua basalis and extravillous trophoblast 
cells.Normal autologous term decidua and peripheral blood were obtained on the day 
of elective or repeat Caesarian (C)-section.   All tissue collected for histology was 
either snap-frozen in liquid nitrogen and subsequently fixed in 4% paraformaldehyde 
for 20 minutes after sectioning, or pre-fixed for 4 hours in 4% paraformaldehyde and 
soaked in 18% sucrose for 18-24 hours prior to freezing.  In addition, blood and 
decidual tissue were processed for lymphocyte isolation as described below.       
 
Immunofluorescence  
Ten µm-thick tissue sections were cut on a cryostat and placed in duplicate 
onto lysine-coated slides.  After blocking of non-specific antibody binding sites in 2% 
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rabbit serum, 50% SuperBlock (Pierce, Rockford, IL), and 0.2% Triton-X-100 (Fisher 
Scientific, Pittsburgh, PA), tissue sections were incubated with an anti-PD-1 antibody 
(10µg/mL, clone J116; eBioscience, San Diego, CA) or its isotype control (mouse 
IgG1κ; BD Pharmingen, San Jose, CA) overnight at 4ºC followed by incubation with 
Alexa 568 rabbit anti-mouse secondary antibody (Invitrogen, Carlsbad, CA) for one 
hour at room temperature.    Tissues were then incubated with CD3-fluorescein 
isothiocyanate (FITC)  (10µg/mL, clone UCHT-1; BD Pharmingen,) or its isotype 
(mouse IgG1κ –FITC; eBioscience) at 37ºC for one hour.  Slides were coverslipped 
with Prolong Gold (Invitrogen) and cured overnight before imaging. 
Immunofluorescence was visualized on a Nikon 90i upright microscope via mercury 
fluorescent excitation then confirmed via confocal scanning (Nikon C1 series 
confocal scan head) (Nikon, Melville, NY). Lasers used for emission detection were a 
488 Multiline Argon (green IR) and 561 Diode laser (red IR), acquisition via the 
Nikon EZ-C1 series software (3.60).  For quantification of single and double positive 
cells, images were captured from 10 randomly chosen, non-overlapping viewing 
fields (40x objective) for each tissue.  Double-positive cells were confirmed by 
comparison of single color scans for each image.  Samples from seven different 
patients were examined for each tissue group.   
 
Isolation of decidual and peripheral blood lymphocytes  
Term decidua was obtained by either peeling the fused decidua 
capsularis/parietalis (decidua) and chorion from the amnion for flow cytometric 
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studies or by scraping the decidua from the chorion for mRNA and in vitro co-
cultures. Decidual tissues were then dissociated using 200 U/mL type IV collagenase, 
1 mg/mL type1-S hyaluronidase, and 150 µg/mL type IV DNAse in a shaking 37oC 
water bath (Vince et al. 1990).  All enzymes were purchased from Sigma-Aldrich.  
Both first trimester and term cell suspensions were layered over Histopaque (Sigma-
Aldrich) and centrifuged. The mononuclear cell fraction, which included decidual 
lymphocytes and chorionic trophoblasts, was collected and counted to assess cell 
viability and yield. For mRNA analysis and in vitro assays, the mononuclear cell 
fraction was collected and plated for 2-3 hours at 37˚C to allow adherence of non-
lymphocytes. For preparation of term autologous peripheral blood lymphocytes, 
samples were diluted in PBS, layered over Histopaque, collected and counted to 
assess cell viability and yield.  
 
Flow cytometry  
Dispersed decidual lymphocytes, chorionic trophoblast cells, and peripheral 
blood lymphocytes were labeled for specific markers using the following anti-human 
antibodies from eBioscience: CD4- FITC (clone RPA-T4), CD8- phycoerythrin (PE) 
(clone RPA-T8), CD25- allophycocyanin (APC) (clone BC96), FoxP3-PE (clone 
PCH101), PD-1-biotin (clone J116), and B7-H1-biotin (clone M1H1).  Biotinylated 
antibodies were detected using a conjugate of phycoerythrin-Cy5 (PE-Cy5) bound to 
streptavidin (BD Pharmingen). Fluorophore-conjugated mouse IgG1 isotype controls 
were used for CD4, CD8, and CD25; PE-conjugated rat IgG2a control was used for 
 40 
FoxP3 (eBioscience).   A minimum of 20,000 lymphocytes were gated based on 
forward and side scatter characteristics as well as T cell subpopulation marker 
expression and data were collected for each desired population.  Samples were 
processed on a BD LSRII instrument and analyzed using FACS Diva software (BD 
Pharmingen).   
 
Fluorescence-activated cell sorting 
Peripheral blood mononuclear cells and non-adherent decidual mononuclear 
cells were labeled for specific markers using the following anti-human antibodies 
from eBioscience: anti-CD3 allophycocyanin (clone UCHT-1), anti-CD4-fluorescein 
isothiocyanate (FITC) (clone RPA-T4), anti-CD8- phycoerythrin (PE) (clone RPA-
T8). Lymphocytes were sorted into CD3+/CD4+ or CD3+/CD8bright populations using 
a BD FACS Aria using FACS DIVA software (Becton Dickinson).  Cell population 
purity for five samples was analyzed post-sorting and was an average of 96.0 ± 1.22 
% for CD3+/CD4+ cells and 97.2  ± 0.61 % for CD3+/CD8bright cells.   
 
Isolation, reverse transcription and PCR analysis of RNA 
After sorting of specific T cell subpopulations, total cellular RNA was isolated 
from each group of cells using Trizol (Invitrogen) according to the manufacturer's 
instructions.  Following quantification by spectrophotometry, 1 µg of RNA was 
reverse transcribed using MMLV reverse transcriptase and oligo-dT primers 
(Invitrogen) in a 40 µl reaction volume. RNA was also added to a reaction without 
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MMLV reverse transcriptase as a control to ensure the absence of genomic DNA 
amplification.  PCR amplification of cDNA products was performed using Taq DNA 
polymerase (Invitrogen) in conjunction with primers (forward: 5' 
GCGGCCAGGATGGTTCTTA-3' ; reverse: 5'-TACTCCGTCTCGTCAGGA-3'), 
which correspond to positions 125-143 and 793-811 of the PD-1 mRNA transcript, 
respectively (GenBank Accession No. NM-005018) (Nielsen et al. 2005).    PCR 
reaction products (20 µL) were subjected to electrophoresis on a 2% 3:1 agarose gel 
(Amresco, Solon OH) and visualized using ethidium bromide (Sigma-Aldrich) to 
examine product size.    Following visualization, products were excised and 
sequenced to confirm identity.   
 
Real-time PCR   
The following PD-1 isoform-specific primers were used: full length PD-1 
(forward: 5’ CTCAGGGTGACAGAGAGAAG 3’, positions 492-511 of PD-1 
mRNA transcript;  reverse: 5’ GACACCAACCACCAGGGTTT 3’,  positions 568-
587); PD-1 Δ  Exon 2 (forward: 5’ GGTTCTTAGAGAGAAGGGCA 3’, positions 
135-144 and 505-515; reverse: 5’ AGGGTGACAGGGACAATAGG 3’, positions 
568-587); PD-1 Δ Exon 3 (forward: 5’ AGGGTGACAGGGACAATAGG 3’, 
positions 495-504 and 661-670; reverse: 5’ CCATAGTCCACAGAGAACAC 3’, 
positions 720-739); PD-1 Δ  Exon 2,3 (forward: 5’ TGGTTCTTAGGGACAATAGG 
3’, positions 135-144 and 661-670; reverse 5’ TCTTCTCTCGCCACTGGAAA 3’, 
positions 749-768); and PD-1 Δ  Exon 2,3,4 (forward: 5’ 
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TGGTTCTTAGAAGGAGGACC 3’, positions 135-144 and 696-705; reverse 5’ 
TCTTCTCTCGCCACTGGAAA, positions 749-768) (Nielsen et al. 2005).   βactin 
primers were purchased from Applied Biosystems (Foster City, CA).  These primers 
were used along with Power SYBR Green PCR Master Mix (Applied Biosystems) 
and 1µL of reverse transcribed RNA.  As a negative control, 1µL of water was 
substituted for cDNA.  Reactions were run for 40 cycles in an ABI Prism 7900 
Sequence Detection System (Applied Biosystems). Threshold cycle (Ct) values were 
obtained for each reaction and compared to those of a standard curve generated from 
decidual T cell cDNA to determine the relative abundance of the amplified product.  
All values were normalized to relative abundance values of β-actin products.  The 
identity of PD-1 isoform products was confirmed by sequence analysis.   
 
Jar cell transfectants 
The full length coding sequence for B7-H1 (Dong et al. 1999) was subcloned 
into a pcDNA3.1 expression vector (Invitrogen) containing a neomycin resistance 
cassette.   Expression vectors with or without coding sequences were then stably 
transfected into Jar choriocarcinoma cells, which lack endogenous B7-H1 expression 
(Petroff et al. 2003).  Jar/V (vector only) and Jar/B7 (B7-H1 expressing) cell lines 
were maintained under selective pressure 300 µg/mL neomycin in RPMI containing 
10% FBS and antibiotics.  To ensure consistency of the presence (Jar/B7) and 
absence (Jar/V) of B7-H1 expression, both cell lines were routinely evaluated by flow 
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cytometry using a PE-conjugated anti-B7-H1 antibody (clone MIH1) and PE-
conjugated Mouse IgG1κ isotype control (eBioscience).    
 
Trophoblast/lympocyte co-culture 
Transfected Jar cells were irradiated (2000 rad) and plated overnight in 
neomycin-containing selective medium at a density of 5,000 cells/well in a 48 well 
tissue culture plate.  The following day, Jar cells were washed with fresh culture 
media to remove neomycin from the culture wells, and sorted CD4+ or CD8bright 
decidual T cells were plated at a density of 275,000 cells/well in 500 µL of culture 
media containing 3 µg/mL phytohemagglutinin (PHA) (Sigma-Aldrich).  Co-cultures 
were placed at 37ºC for 72 hours, after which cell culture supernatants were collected 
and stored at -80°C.   To evaluate the effect of B7-H1 on cell proliferation in separate 
co-cultures, sorted decidual T cells were labeled with 5µM of carboxyfluorescein 
succinimidyl ester (CFSE) (Invitrogen) according to the manufacturers instructions 
and then placed into culture with transfected Jar cells as described above.   
 
Analysis of cytokine production 
Analysis of IFN-γ, TNF-α, interleukin (IL)-2 and interleukin (IL)-10 
concentrations in cell culture supernatants was performed using a multiplex 
Beadlyte® Human Multi-Cytokine Detection System (Upstate/Millipore, Billerica, 
MA) according to the manufacturer’s instructions.  Samples were processed on a 
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Luminex® 200 instrument and data were analyzed using Luminex IS software 
version 2.3 (Upstate). 
 
Evaluation of apoptosis and proliferation  
              In experiments evaluating apoptosis or cell proliferation after the 72 hour co-
culture, decidual T cells in the supernatant were collected and labeled with APC-
conjugated anti-human CD3 antibody (eBioscience), and LIVE/DEAD® Fixable 
Violet Dead Cell Stain Kit (Invitrogen). For samples to be analyzed for apoptosis, 
cells were also stained with PE-conjugated Annexin V (BD Pharmingen).  All 
samples were processed on a BD LSRII instrument and analyzed using FACS Diva 
software (BD Pharmingen).  For apoptosis evaluation, CD3+ cells with a violetbright 
and Annexin+ phenotype were designated as apoptotic.  In separate experiments, cell 
proliferation was quantified by evaluating the CFSE profiles of CD3+ cells.   
 
Statistics 
 Statistical significance was determined using either a one-way analysis of 
variance (ANOVA) with a Student-Newman-Keuls post hoc analysis (cell counts 
from immunohistochemistry) or two-way ANOVA with either a Fisher's LSD (flow 
cytometry) or Tukey post hoc analysis (semi-quantitative real-time PCR, multiplex 
cytokine analysis).  Differences were considered significant at α = 0.05.   
 
D. Results 
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PD-1 is expressed on decidual T cells throughout pregnancy  
Because of the high level of B7-H1 expression on human fetal trophoblast 
cells, we examined whether CD3+ T cells at the maternal-fetal interface express its 
cognate receptor, PD-1. Using double fluorescence immunohistochemistry, we 
examined both PD-1 and CD3 expression in normal secretory phase endometrium (n 
= 6), first trimester decidua, and term extraplacental membranes and basal plate (n=7 
per group) (Fig. 2.1).  We then enumerated cells positive for one or both markers 
(Fig. 2.2), noting that the signal intensity for both CD3 and PD-1 varied within 
individual sections in all tissues.   In agreement with other observations (Haller et al. 
1993; Morii et al. 1993; Mincheva-Nilsson et al. 1994; Vassiliadou et al. 1996; 
Sindram-Trujillo et al. 2004) CD3+ cells were present in secretory phase 
endometrium as well as first trimester and term decidua ( Fig 2.1 A-E).  While the 
number of CD3+ T cells per image did vary (Fig 2.1), the overall number of CD3+ 
cells counted did not differ significantly between tissue groups (p = 0.849).    
When examining PD-1 expression, we next observed that ≥ 96% of PD-1+ 
cells were also CD3+ (Fig. 1), suggesting that the majority of the PD-1-expressing 
cells were T cells. Further analysis revealed that the percentage of CD3+ cells 
expressing PD-1 was low in non-pregnant secretory endometrium (Fig 2.1 A, Fig 
2.2), but increased significantly in first trimester decidua (Fig. 2.1 B, Fig. 2.2), with 
no apparent difference between first trimester decidua parietalis and basalis.  The 
abundance of PD-1+CD3+ cells remained elevated in late gestation (Fig. 2.1 C-E; Fig. 
2.2), and was significantly higher in term decidua associated with fetal membranes as 
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compared to first trimester decidua (Fig. 2.2).   We also examined PD-1 expression 
on peripheral blood T cells from patients in first trimester (n = 4,) and term pregnancy 
(n = 8) by flow cytometry; the proportion of PD-1+ T cells was low in first trimester 
blood and did not change significantly in late gestation  (P  > 0.05; Fig. 3 and data not 
shown).   In summary, these data, suggest that PD-1 expression is induced locally on 
decidual T cells during pregnancy.   
 
PD-1-expressing T cell subpopulations are specifically localized in the decidua  
We further examined whether PD-1 expression was specifically induced at the 
maternal-fetal interface by evaluating decidual and peripheral blood samples from the 
same patients at term pregnancy.  Additionally we examined which T cell 
subpopulations express PD-1.   Figure 2.3 shows the flow cytometric analysis of 
CD8bright (n=6), CD4+ (n=8), and CD4/CD25/FoxP3+ (TReg)  (n=8) lymphocyte 
populations in peripheral blood just before normal term C-section delivery and 
autologous term decidual tissue collected after delivery.  Each of these populations 
was easily identifiable in both peripheral blood and decidua; as expected (Tilburgs et 
al. 2006), TReg  were more abundant in decidual tissue than in peripheral blood 
(6.65% vs 0.64% respectively, P = 0.007).  Further analysis by flow cytometry 
consistently revealed that cell surface-associated PD-1 was more abundant on 
decidual T cells than on peripheral blood T cells from the same patient; this was true 
for each of the three populations examined (Fig. 2.3 A-C).  Figure 2.3 D shows the 
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combined data for all patients, and statistical analysis revealed that differences in PD-
1-expressing T cells between decidua and blood were highly significant.  
To confirm the specificity of our findings of PD-1 expression on T cells, we 
stained decidual and peripheral blood samples with antibodies against CD3, CD4, 
CD8 and a second clone of an anti-PD-1 antibody (clone MIH4, eBioscience).  
Through flow cytometric analysis, we observed a similar preferential expression of 
PD-1 in decidual CD3+/CD4+ and CD3+/CD8bright T cell populations when compared 
to peripheral blood (n=2, data not shown).  Also, to verify that decidual cell 
populations examined were resident within the decidua, we routinely labeled cells 
with an anti-human CD19 antibody (clone HIB19, eBioscience) using peripheral 
blood as a positive control.  As expected (Mincheva-Nilsson et al. 1994), purified 
decidual lymphocytes completely lacked CD19+ B cells, confirming little or no 
peripheral blood contamination of decidual tissues (data not shown).   
 
PD-1 mRNA isoforms are preferentially expressed in decidual T cell subpopulations 
Because these data suggested that decidual T cells preferentially express the 
PD-1 surface protein (Fig. 2.2,2.3), we next examined whether term decidual and 
peripheral blood T cells express different repertoires of PD-1 mRNA isoforms.  
Conventional RT-PCR analysis of mRNA from peripheral blood and decidual CD4+ 
or CD8+ T cell subpopulations showed two amplicons, each of which were sequenced 
and identified as the full length (FL PD-1) and soluble (PD-1 Δ Ex 3) isoforms of the 
PD-1 mRNA transcript (Fig. 2.4A).   In separate experiments using semi-quntatitive 
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real-time PCR and isoform specific primers, we found that the full length PD-1 
mRNA transcript was more abundantly expressed in decidual T cells when compared 
to autologous peripheral blood T cells at term pregnancy (n = 5) (Fig. 2.4 B).  This 
was true of both CD4+ and CD8bright T cell subpopulations, and was consistent with 
our observations for PD-1 surface expression in decidual T lymphocytes (Fig. 2.3).  
The ∆ Ex3 PD-1 isoform was also expressed more abundantly in decidual CD4+ and 
CD8bright T cells.  Three other PD-1 mRNA isoforms were detectable by real-time 
PCR in both peripheral blood and decidual lymphocytes, and although the sequence 
of each isoform was verified (Nielsen et al. 2005), the abundance of all transcripts 
was too low to confidently assess quantity (data not shown).   
 
Effects of B7-H1 on term decidual T cells 
Because B7-H1 is abundantly expressed on placental trophoblast cells (Petroff 
et al. 2003; Petroff et al. 2005b) and PD-1 is preferentially expressed by decidual T 
cells at term pregnancy (Fig. 2.2-2.4), we examined the effects of B7-H1-expressing 
cells on term decidual T lymphocyte apoptosis, proliferation and cytokine production.  
We established a co-culture system with B7-H1-transfected Jar choriocarcinoma cells 
and decidual CD4+ and CD8bright T cells.   B7-H1 expression was routinely monitored 
on control transfected (Jar/V) or B7-H1-transfected (Jar/B7) cells by flow cytometry 
and found to be highly expressed on the surface of Jar/B7 cells, as it is on primary 
chorionic trophoblast cells (n=5, Fig. 2.5 A) (Petroff et al. 2003).   
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When evaluating the influence of B7-H1 on decidual T cell death, Jar/B7 co-cultures, 
when compared to Jar/V, did not increase the percentage of either CD4+ or CD8bright T 
cells undergoing apoptosis (n=5, Fig. 2.5 B).  Further, decidual T cell proliferation, 
quantified by CFSE analysis, was similar between Jar/V and Jar/B7 co-cultures (n=2, 
data not shown).  Examination of cytokine production revealed that decidual T cell 
secretion of IFN-γ and IL-10 was increased in the presence of Jar/V (n=6, Fig. 2.6). 
However, B7-H1-transfected Jar cells reversed the stimulatory effect on IFN-γ and 
TNF-α in CD4+ T lymphocytes while having no significant effect on the production 
of IL-10 from these cells (Fig. 2.6).  In contrast, Jar/B7 cells did not significantly 
influence the secretion of any cytokines from CD8+ T cells (Fig. 2.6).  
Interleukin(IL)-2 secretion was also evaluated, but its concentration was below 
detectable limits in all co-cultures examined, suggesting that decidual T cells could 
not be induced to secrete this cytokine.  Additionally, Jar/V or Jar/B7 cells cultured 
without T cells did not secrete any detectable IFN-γ, TNF-α, IL-10, or IL-2 (n=4, data 
not shown).    
 
E. Discussion 
Through these studies we have identified a novel location and potential 
function of the CD28 family molecule, PD-1, at the maternal-fetal interface. While 
we found PD-1 to be expressed on a small percentage of T cells in the secretory phase 
endometrium, there was a significant increase in PD-1+ CD3+ cells in first trimester 
and term decidua (Fig. 2.1, 2.2). This induction of PD-1 expression was specific to 
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the decidua, as autologous term pregnancy decidual samples contained significantly 
higher percentages of PD-1+ T cells than their peripheral blood counterparts (Fig. 
2.3).  Indeed, peripheral blood samples from patients in both first trimester and term 
pregnancy contained low percentages of PD-1+ T cells (Fig. 2.3), similar to non-
pregnant peripheral blood (Hatachi et al. 2003).  Taken together these data suggest 
that pregnancy-specific factors up-regulate the expression of this receptor 
preferentially at the maternal-fetal interface. PD-1 is known to be induced via 
mechanisms including CD3 stimulation, antigen recognition and hormones (Agata et 
al. 1996; Isogawa et al. 2005; Polanczyk et al. 2006).   Surface PD-1 can be up-
regulated on T cells by specific antigen stimulation (Isogawa et al. 2005), thus 
exposure to fetal antigen may induce PD-1 expression in decidual T cells during 
pregnancy.   Others have reported that PD-1 expression may be under hormonal 
regulation (Polanczyk et al. 2006), therefore elevated hormone levels throughout 
gestation could also influence PD-1 expression in the gravid uterus.   
The preferential expression of PD-1 receptor by decidual T cells in both first 
trimester and term pregnancy complements our previous studies in which we 
observed expression of the its ligand, B7-H1, on trophoblast cell populations 
throughout gestation and hypothesized that placental B7-H1 serves as a molecular 
shield against maternal alloresponses to the fetus (Petroff et al. 2003; Petroff et al. 
2005b). The expression of PD-1 on both decidual CD8bright  and CD4+ T cells in first 
trimester and term pregnancy samples supports the hypothesis that these cells could 
be targets for trophoblast B7-H1-mediated regulation during pregnancy.  Indeed, in 
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vitro and in vivo studies have shown B7-H1:PD-1-mediated inhibition of allogeneic 
immune responses and amelioration of allograft rejection, including anti-fetal 
responses (Ozkaynak et al. 2002; Latchman et al. 2004; Guleria et al. 2005). 
Along with CD8bright and CD4+ T cells, PD-1 was preferentially expressed on 
decidual TReg (Fig. 3B).  PD-1 expression by TReg  has been previously documented 
(Raimondi et al. 2006), and two recent studies have suggested that B7-H1 expression 
on parenchymal cells may induce differentiation of naïve CD4+ T cells into TReg 
outside of the thymus (Krupnick et al. 2005; Beswick et al. 2007).  TReg are a 
significant population in the decidua, are associated with the success of human 
pregnancy, and are required for allogenic murine pregnancies (Aluvihare et al. 2004; 
Heikkinen et al. 2004; Sasaki et al. 2004; Darrasse-Jeze et al. 2006; Tilburgs et al. 
2006).  While the function of PD-1 on TReg is unclear, its presence could be a 
reflection of their differentiation, and raise the interesting possibility that trophoblast 
B7-H1 may induce naïve CD4+ T cells to differentiate into TReg in order to promote 
immune tolerance of the fetal allograft.   
The preferential expression of PD-1 by decidual CD4+ and CD8bright T cells 
was confirmed at the mRNA level where the full length PD-1 transcript was 
upregulated in decidual T cells compared to peripheral blood. Interestingly, the PD-1 
Δ Ex3 transcript was also more abundantly expressed in decidual T cells (Fig. 2.4 B).  
Because the PD-1 Δ Ex3 transcript encodes a soluble form of the receptor that may 
prevent T cell inhibition by acting as a decoy (Wan et al. 2006), its upregulation by 
decidual T cells was somewhat unexpected.  While expression of this isoform may be 
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a safeguard against over-suppression of decidual T cells in order to maintain their 
physiological activity (Piccinni et al. 1998; Scaife et al. 2006),  it  will be interesting 
to examine PD-1 Δ Ex3 in pregnancy pathologies such as recurrent spontaneous 
abortion where endometrial/decidual T cells may be activated (Maruyama et al. 1992; 
Vassiliadou et al. 1999; Quack et al. 2001).  
In regard to the function of PD-1 during pregnancy, we also examined 
whether its ligand, B7-H1, could alter cytokine secretion or apoptosis of decidual T 
cells as a potential means of modifying maternal immune activation (Freeman et al. 
2000; Dong et al. 2002).  In co-culture experiments we observed that the Jar/V cells 
caused increased cytokine production in the decidual T cells (Fig. 2.6), which 
parallels a previous study showing that Jar cells can induce production of IL-10 and 
TNF-α in uterine natural killer cells (Rieger et al. 2001).   We also observed that B7-
H1 expression on Jar cells selectively inhibited secretion of IFN-γ and TNF-α in 
CD4+ but not CD8bright decidual T cells (Fig. 2.6).  CD4+ T helper cells control 
activation of antigen-presenting cells and CD8+ T cells through cytokine secretion, 
and therefore it may be particularly important to modify the cytokine repertoire of 
these cells in order to control maternal anti-fetal immune reactions.  The lack of effect 
of B7-H1 on IL-10 production in either cell type (Fig. 2.6) suggests that B7-H1 is 
causing selective inhibition, rather than a global suppression, of decidual T cytokines. 
Consistent with this finding, B7-H1 also did not increase the percentage of T cells 
undergoing apoptosis (Fig. 2.5 B). 
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A balance of cytokine production appears to be critical in promoting 
pregnancy.   For example, overproduction of IFN-γ and TNF-α is associated with 
preterm labor and recurrent spontaneous abortions in humans as well as fetal rejection 
in mice (El-Shazly et al. 2004; Mjihdi et al. 2004; Kim et al. 2005).  On the other 
hand, the same cytokines may also control trophoblast invasion in early pregnancy, 
and play a role in parturition at term (Pollard et al. 1993; Buonocore et al. 1995; 
Ashkar et al. 2000; Fukushima et al. 2003; Cohen et al. 2006; Scaife et al. 2006).  
Anti-inflammatory cytokines also have a critical role at the maternal-fetal interface as 
a reduction or absence of IL-10 is associated with chronic human pregnancy failure 
and potentiation of inflammation-induced murine fetal loss (Piccinni et al. 1998; 
Murphy et al. 2005; Robertson et al. 2007).   The B7-H1:PD-1 pathway may 
selectively modify decidual T cell cytokine secretion in order to maintain a proper 
immunological environment at certain times during pregnancy while still allowing for 
appropriate physiological functions throughout gestation.  
In conclusion, these studies identify a novel location of the PD-1 receptor at 
the maternal-fetal interface, highlight potential targets of B7-H1-mediated regulation 
and demonstrate that the B7-H1:PD-1 pathway is present and functional for 
modification of the maternal immune system during pregnancy.   
 
Acknowledgments 
The authors would like to thank the following individuals: L. Holets and E. 
Kharatyan for technical assistance, E. Roach for imaging assistance, J. Ballenger 
 54 
(Dept. of Pathology) for endometrial samples, J. Vu (Dept. of Obstretics and 
Gynecology) for patient sample collection, and C. Ober, C. Billstrand, M. Gilliam, L. 
Bennett, and E. Quansah at the University of Chicago for assistance with collection of 
first trimester decidual samples.  Further resources and services were provided by the 
KUMC Center for Reproductive Sciences (NICHD), the KUMC Center Flow 
Cytometry Core (NCRR), the KUMC COBRE program in Cell Development and 
Differentiation (P20RR024214), the Kansas State University COBRE program in 
Epithelial Function (P20RR017686), the Kansas INBRE (P20RR016475). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 55 
F. Figures and Legends 
Figure 2.1.  PD-1 expression in endometrial and decidual tissues……………….57 
Figure 2.2  Quantification of PD-1-expressing T cells in endometrial and decidual  
tissues……………………………………………………………….59 
Figure 2.3  Flow cytometry of PD-1-expressing T cell subpopulations in term  
peripheral blood and decidua……………………………………….61 
Figure. 2.4.  RT-PCR analysis of PD-1 mRNA isoforms in autologous term  
peripheral blood and decidual T cells………………………………63 
Figure 2.5.  Analysis of B7-H1-mediated effects on decidual T cell apoptosis…65 
Figure 2.6.  Cytokine assay analysis of B7-H1 mediated effects of decidual T cell  
cytokine production…………………………………………………67 
 
 
 
 
 
 
 
 
 
 
 
 56 
Figure 2.1. PD-1 expression in endometrial and decidual tissues.   Double 
immuno-fluorescent immunohistochemistry of normal secretory endometrial tissues 
(A), first trimester decidua (B), term basal plate (C) and term extraplacental 
membranes (D,E) with antibodies against CD3 (green color), PD-1 (red color).  (A-
E): Photomicrographs are representative images of CD3 and PD-1 immunolabeling 
for each group of tissues. (F): representative isotype control image from 
extraplacental membranes. Arrows indicate double positive cells.  Bars, 50 µM.  
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Figure  2.2.  Quantification of PD-1-expressing T cells in endometrial and 
decidual tissues.  Graph represents mean percentages of PD-1+CD3+ cells in each 
tissue type (SE, n = 6; FT, TBP, TM, n = 7/group).  Bars, SEM. SE, secretory 
endometrium; FT, first trimester decidua; TBP, term basal plate; TM, term 
extraplacental membranes. Comparisons for which no P value is given were not 
significantly different (P > 0.05).  
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Figure 2.3.  Flow cytometry of PD-1-expressing T cell subpopulations in term 
peripheral blood and decidua.  Histograms are representative images of flow 
cytometry in autologous peripheral blood (top panels of A-C) and decidual samples 
(bottom panels of A-C).  Bars represent boundaries of gating for each T cell 
subpopulation marker (left panels of A-C) and PD-1 (right panels of A-C). Solid lines 
represent isotype controls for CD4 and CD8 and fluorescence-minus-one controls for 
PD-1.  (A) Left panels: CD8 expression on lymphocytes; right panels: PD-1 
expression on CD8Bright populations.  (B) Left panels: CD4 expression on 
lymphocytes; right panels: PD-1 expression on CD4+ population.  (C) Upper right 
quadrant of dot plot represents gated CD4+CD25+FoxP3+ population for PD-1 
expression analysis.  Left panels: CD25 and FoxP3 expression on CD4+ lymphocytes; 
right panels: PD-1 expression on the CD4+CD25+FoxP3+ population. (D) Combined 
data from a minimum of 6 different patients.  Boxes: 10th to 90th percentile values of 
the data set; solid lines in box: mean value; dotted lines in box: median value; bars: 
range of values for each data set.   
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Figure 2.4.  RT-PCR analysis of PD-1 mRNA isoforms in autologous term 
peripheral blood and decidual T cells. (A) Agarose gel analysis of RT-PCR using 
PD-1 and b-actin specific primers.  PB, Peripheral blood.  Dec, Decidua. (B) Graphs 
represent semi-quantatitive real-time PCR analysis of cDNA (n=5 patients) using PD-
1 mRNA isoform-specific primers.  Samples were normalized to β-actin expression.  
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Figure 2.5. Analysis of B7-H1-mediated effects on decidual T cell apoptosis.  (A) 
Representative histograms from flow cytometric analysis of B7-H1 expression in 
control (Jar/V) or B7-H1-transfected (Jar/B7) cells and primary chorionic trohpoblast 
cells (Primary CTB).  (B) Analysis of B7-H1 effects on decidual T cell apoptosis.  
Graphs represent mean percentages of apoptotic T cells from 6 different patients.  
Bars, SEM.  
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Figure  2.6.  Cytokine assay analysis of B7-H1 mediated effects of decidual T cell 
cytokine production. Graphs represent mean values of decidual T cell cytokine 
secretion from a minimum of 5 different patients.  Bars: SEM.  
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A. Abstract 
        Several immunoregulatory mechanisms are in place during pregnancy to protect 
the semi-allogeneic fetus from the maternal immune system. Of these, the 
suppression maternal T cell activity by CD4+CD25+ and FoxP3+ regulatory T cells 
(Treg) is one of the most potent as they prevent rejection of semi-allogeneic fetuses in 
murine pregnancy.  In humans, Treg are preferentially localized within decidual tissues 
as compared to peripheral blood, and a reduction in these cells within the decidua is 
associated with recurrent miscarriage.  As the mechanisms responsible for Treg 
abundance and localization during pregnancy incompletely understood, we asked 
whether cytotrophoblast cells (CTB) could directly influence expansion of Treg.   
Peripheral blood naïve CD4+ T cells were co-cultured with CTB followed by flow 
cytometric analysis of Treg markers.  CTB caused a 3-fold induction of the percentage 
of CD4+CD25 bright FoxP3+ cells (P < 0.001, n = 6) after 7-day culture. To test 
whether a syncytiotrophoblast phenotype altered the expansion of Treg, we also 
cultured naïve CD4+ T cells with CTB treated with epidermal growth factor (EGF). 
The percentage of Treg did not differ significantly between co-cultures with untreated 
and EGF-treated CTB, suggesting that trophoblasts induce Treg expansion regardless 
of their differentiation status.  Re-purified CD4+CD25+ cells from these cultures were 
also were capable of suppressing proliferation of autologous CD4+ T cells in vitro. 
These studies raise the possibility that the fetal trophoblast may drive expansion of 
Treg during pregnancy as a potential means of controlling the maternal immune 
system.   
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B. Introduction 
Regulatory T cells (Treg), defined by their CD4+CD25+FoxP3+ phenotype, are 
powerful modulators of autologous T cell activity, and are critical in maintaining self-
tolerance and preventing autoimmune disease (Sakaguchi 2000; Shevach 2002). 
These cells suppress T cell activity primarily through contact- dependent mechanisms 
(Thornton et al. 1998; Sasaki et al. 2004) and can be divided into central and 
peripheral subclasses based on their developmental origin (Abbas 2003). Central Treg 
develop within the thymus through a widely accepted mechanism involving T cell 
receptor (TCR) engagement of self major histocompatability molecules (MHC) and 
peptides (Jordan et al. 2001; Apostolou et al. 2002; Hsieh et al. 2006).  Peripheral Treg 
mature extra-thymically, through either proliferation of a pre-cursor population or de 
novo differentiation from naïve CD4+ T cells, expanding in peripheral tissues, 
particularly during pathological conditions involving viral infections and 
tumorgenesis (Pillai et al. 2007).  
Pregnancy is a physiological condition also associated with high numbers of 
peripheral Treg.  These cells localize preferentially to the decidual tissues within the 
human maternal-fetal interface (Tilburgs et al. 2006) and decidual Treg are 
significantly reduced in decidual bed biopsies from spontaneously aborted and pre-
eclamptic pregnancies (Sasaki et al. 2004; Sasaki et al. 2007).   In murine pregnancy, 
depletion of Treg causes T cell-mediated fetal rejection in allogeneic but not syngeneic 
fetuses (Aluvihare et al. 2004; Darrasse-Jeze et al. 2006), further confirming the 
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critical role of these cells in maintaining maternal tolerance to the semi-allogeneic 
fetus.   
The localization of Treg in human pregnancy was recently re-examined 
(Tilburgs et al. 2008) and CD4+CD25brightFoxP3+ cells  appear to be less abundant in 
the peripheral blood of pregnant women compared to non-pregnant controls. The 
decrease in circulating Treg coupled with a preferential localization of these cells in 
autologous decidual tissues suggests that decidual Treg are recruited from peripheral 
blood (Tilburgs et al. 2008).  However, the high relative abundance of Treg within the 
decidua also suggests that other mechanisms may influence their localization within 
this tissue.  
In the current study, we examined whether Treg could also be expanded by 
factors present within the human maternal-fetal interface.  Among the numerous cells 
within the human placenta and decidua that could contribute to this process, the fetal 
trophoblast is a strong candidate.  These cells express several surface associated and 
soluble molecules that are known to induce regulatory T cell expansion.  For 
example, B7-H1, a member of the B7 co-stiumlatory family, is highly expressed on 
numerous trophoblast cell types in the human placenta (Petroff et al. 2003; Petroff et 
al. 2005b) and may be involved in Treg differentiation in peripheral tissues (Krupnick 
et al. 2005; Beswick et al. 2007). In addition, the B7-H1 receptor, PD-1 is 
preferentially expressed on decidual CD4+ and Treg populations (Taglauer et al, in 
press).  Trophoblast cells also secrete other proteins and hormones that could 
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influence Treg expansion, including HLA-G, TGF-β and estrogen (Graham et al. 
1992; Morales et al. 2003; Pasqualini 2005).  
Because trophoblasts express a unique combination of cell surface and soluble 
factors known to influence Treg proliferation or differentiation, we hypothesized that 
these cells induce expansion of Treg as a means of enabling immune regulation within 
the human maternal-fetal interface.   To this end, we co-cultured naïve CD4+ T cells 
with primary cytotrophoblast cells.  Following culture, we examined the T cells for 
expression of Treg markers and evaluated whether they obtained suppressive 
capabilities.  
 
C. Materials and methods 
Tissue collection 
All tissue samples were collected in accordance with human subjects 
protocols approved by the University of Kansas Medical Center Institutional 
Research Board (HSC #3037). Placental/decidual tissues and peripheral blood were 
collected from healthy patients on the day of elective or repeat Caesarian (C)-section; 
peripheral blood was also collected from healthy male donors, ages 25-40.   
 
Lymphocyte and trophoblast isolation  
Term decidual lymphocytes were obtained by peeling the fused decidua 
capsularis/parietalis (decidua) and chorion from the amnion. Decidual tissues were 
then dissociated using 200 U/mL type IV collagenase, 1 mg/mL type1-S 
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hyaluronidase, and 150 µg/mL type IV DNAse in a shaking 37oC water bath (Vince 
et al. 1990).  All enzymes were purchased from Sigma-Aldrich. Dissociated cell 
suspensions were layered over Histopaque (Sigma-Aldrich) and centrifuged. The 
mononuclear cell fraction was collected and counted to assess cell viability and yield. 
For preparation of term autologous peripheral blood lymphocytes, samples were 
diluted in PBS, layered over Histopaque, collected and counted to assess cell viability 
and yield.  
For isolation of primary cytotrophoblast cells, 30-40g villous tissue was 
dissected, rinsed, and enzymatically digested as described previously (Petroff et al. 
2006b). Briefly, minced placental villi were dissociated in three 30-minute stages of 
using trypsin and DNase.  The cell suspension was then layered over a 5-70% 
stepwise Percoll (Sigma-Aldrich) gradient and centrifuged.  The trophoblast fraction 
was collected and subjected to immunopurification by negative selection over 
magnetic bead columns coated with anti-HLA class I antibody (W6/32; BioExpress, 
West Lebanon, NH).  Cells were routinely greater than 95% pure as assessed by 
immunocytochemical staining for cytokeratin-7 (DAKO Corp., Carpinteria, CA). 
 
Co-culture of naïve T cells and primary cytotrophoblasts 
For co-culture experiments, peripheral blood naïve CD4+ T cells were isolated 
by negative selection using a magnetic cell separation kit (Miltenyi Biotec, Auburn, 
CA) according to the manufacturer’s instructions. Purified cytotrophoblast cells 
(CTB) were seeded in duplicate into 48 well plates at a density of 5.25 x 105 
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cells/well in IMDM medium (Sigma-Aldrich, St. Louis, MO) containing 10% FBS 
and antibiotics.  The following day, dead cells were removed by washing with media, 
and freshly isolated naïve CD4+ T cells were plated at a density of 2.1 x 106 cells/well 
in 500 µL of culture media.  Co-cultures were placed at 37oC for 7 days, with fresh 
medium added every 48 hours (Fig. 3.1A,B).  In some experiments, cytotrophoblasts 
were pre-treated with 10ng/mL epidermal growth factor (EGF) (PeproTech, Rocky 
Hill, NJ) for 96 hours before addition of naïve CD4+ T cells, and fresh EGF-
containing medium was added every 48 hours (Fig. 3.1A).  Following culture, cells 
were collected and analyzed by flow cytometry.  
 
Cell proliferation suppression assay 
After seven days in cell culture, CD4+CD25+ T cells were purified from the 
co-cultures by negative selection (CD4) and positive selection (CD25) using a 
magnetic cell separation kit (Miltenyi Biotech). These cells were added to CFSE-
labelled autologous naïve CD4+ T cells at a 1:1 or 1:10 ratio.  Together, the cells were 
cultured for 5 days in uncoated plates or plates coated with anti-CD3 (1 µg/mL OKT-
3, eBiocience, San Diego, CA) and CD28 (0.05 µg/mLclone CD28.2, eBioscience) 
antibodies (Fig. 1B).  
 
Flow cytometry 
For analysis of Treg in either primary decidual/peripheral blood lymphocytes 
or CTB co-cultures, cells were labeled for specific markers using the following anti-
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human antibodies: CD4-fluorescein isothiocyanate (FITC) (clone RPA-T4), CD25- 
allophycocyanin (APC) (clone BC96), and FoxP3-PE (clone PCH101).  The isotype 
control antibodies for this staining included fluorophore-conjugated mouse IgG1 
isotype controls CD4 and CD25 and PE-conjugated rat IgG2a control for FoxP3.  The 
purity of naïve CD4+ T cell isolations for CTB-co-cultures and Treg suppression 
assays was evaluated by labeling cells with antibodies against CD4-FITC (clone 
RPA-T4) and CD45RA-PE (clone HI100), or with corresponding isotype controls 
FITC-mouse IgG1-FITC and IgG2b-PE.  For examination of proliferation within Treg 
suppression assays, cells were labeled with anti-human CD3-APC (clone UCHT-1) 
and CFSE profiles of CD3+ responder cells were analyzed.  All antibodies were 
purchased from eBioscience.  Cells from each experiment were labeled with 
LIVE/DEAD® Fixable Violet Dead Cell Stain Kit (Invitrogen).  A minimum of 
20,000 violet-dim lymphocytes were gated based on forward and side scatter 
characteristics and the data were collected for each desired population.  Samples were 
processed on a BD LSRII instrument and analyzed using BD FACSDiva™ software 
(BD Pharmingen, San Jose, CA). 
 
Statistics 
Statistical significance was determined using two-way analysis of variance 
(ANOVA) with either a Fisher's LSD (peripheral blood and decidual Treg flow 
cytometry) or Student-Newman-Keuls (CTB/naïve T cell co-cultures) post hoc 
analysis.   Differences were considered significant at α = 0.05.   
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D. Results 
We first examined the distribution of Treg in the peripheral blood and decidual 
tissues of pregnant women.  Autologous peripheral blood and decidual lymphocytes 
were collected from patients at term pregnancy and examined for expression of CD4, 
CD25, and FoxP3 via flow cytometry (Fig. 3.2). We found that decidual CD4+ 
lymphocytes contained a higher percentage of CD25+FoxP3+ cells as compared to 
autologous peripheral blood samples (P = 0.007; Fig. 3.2 A,B).  These results are 
consistent with previous reports (Sasaki et al. 2004; Tilburgs et al. 2006; Tilburgs et 
al. 2008) and suggest a preferential localization of Treg to the maternal-fetal interface 
in pregnant women.   
We next asked whether trophoblast cells could cause expansion of Treg.  
Peripheral blood naïve CD4+ T lymphocytes were placed into culture with purified 
primary cytotrophoblast cells (CTB) for seven days followed by flow cytometric 
analysis of CD4, CD25 and FoxP3 expression (Fig. 3.1 A,B). The purity of naïve 
CD4+ T cells was monitored by flow cytrometry and averaged 96.5% ± 0.5 SEM 
CD4+CD45RA+ cells/total lymphocytes (Fig. 3.1 B).  Before co-culture, 
CD4+CD25brightFoxP3+ cells were found in very low abundance among purified naïve 
CD4+ T cells and following culture in medium alone, the percentage of these cells 
was unaltered (P = 0.982) (Fig. 3.3 A,B). However, when naïve T cells were cultured 
with CTB there was a dramatic increase in the abundance of Treg (Fig. 3.3 A), which 
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was highly significant in combined data from 6 different patients (P < 0.001; Fig. 
3B).   
Our results suggest that CTB can expand Treg in vitro. However, in the 
placenta, syncytiotrophoblast cells are anatomically closer to the leukocytes in the 
maternal blood space and phenotypically distinct from CTB (Kaufmann 1982; 
Benirschke 1994; Georgiades et al. 2002).  Therefore we next examined whether 
syncytiotrophoblast cells could also influence expansion of Treg.  To induce the 
syncytiotrophoblast phenotype, we pre-treated primary CTB with epidermal growth 
factor (EGF) for 96 hours prior to culture (Morrish et al. 1987). Naïve CD4+ T cells 
were placed into culture with EGF-treated CTB and EGF was maintained in culture 
conditions throughout the seven day incubation period (Fig. 3.1 A).   Culture in EGF-
containing medium alone did not induce a Treg phenotype (Fig 3.3 A).   In addition, 
while abundance of Treg increased in the presence of EGF-treated CTB (Fig. 3.3 A) 
the percentage of Treg was not significantly different from cultures with 
undifferentiated CTB (P = 0.083; Fig. 3.3 B).  
An additional readout of a Treg phenotype is the capability to suppress 
proliferation of other T cells.  We therefore we examined whether CTB-induced 
could suppress proliferation of CD4+ T lymphocytes. CFSE-labeled naïve CD4+ T 
cells (responders), were placed into culture with decreasing ratios of CD4+ CD25+ 
cells from CTB co-cultures (CTB Treg), and stimulated with antibodies against CD3 
and CD28 (Fig. 3.1 B).   After 5 days, responder cells had undergone up to 5 cell 
divisions, while unstimulated cells had not proliferated  (Fig. 3.4 A).  Addition of 
 78 
CTB-Treg to responder cells resulted in a dose-dependent reduction in proliferation as 
assessed by evaluation of CFSE profiles (Fig. 3.4  A,B).  
 
E. Discussion 
The objective of the current study was to examine the mechanisms responsible 
for the expansion of Treg in pregnancy. Consistent with previous studies (Tilburgs et 
al. 2006), we observed that Treg were more abundant among decidual lymphocytes 
compared to autologous peripheral blood samples (Fig. 3.2).  In addition, primary 
CTB induced expansion of CD4+CD25highFoxP3+ cells (Fig. 3.3).  Purified CD4+ 
CD25+ T cells from CTB co-cultures suppressed the proliferation of autologous CD4+ 
T cells responder cells at 1:1 ratio (Fig. 3.4), an effect that was lost at a ratio of 1:10 
(Treg:responder).  This range is similar to suppressive capacity of human peripheral 
blood Treg in vitro (Tsaknaridis et al. 2003) and suggests that CTB-induced Treg 
inhibit T cell proliferation in a dose-dependent manner.   
Trophoblast-mediated Treg expansion was unaltered by their differentiation 
status (Fig. 3.3). CTB differentiate to become sTB and upon differentiation these cells 
upregulate production of hormones including estrogen and progesterone (Simpson et 
al. 1981; Pepe et al. 1999; Jiang et al. 2005).  Like CTB, sTB produce soluble HLA-G 
and TGF-β (Graham et al. 1992; Morales et al. 2003) and sTB express increased 
levels of cell surface B7-H1 compared to CTB (Petroff et al. 2003).  EGF treatment 
of CTB in vitro mimics sTB differentiation, recapitulating their syncytial phenotype, 
hormone production and increased levels of B7-H1 expression (Morrish et al. 1987; 
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Petroff et al. 2003). Thus in our co-cultures both undifferentiated and EGF-treated 
CTB express several molecules that may directly influence Treg induction.   
Of these, B7-H1 is a strong candidate as its presence on intestinal epithelial 
cells causes differentiation of human naïve CD4+ T cells into Treg (Beswick et al. 
2007).  Human decidual CD4+ and CD4+CD25+FoxP3+ T cells preferentially express 
the B7-H1 receptor, PD-1, compared to their counterparts in peripheral blood 
(Taglauer et al, in press).  While an EGF-mediated increase in B7-H1 expression on 
CTB did not cause a significant change in the abundance of Treg (Fig. 3.3), B7-H1 is 
still expressed by undifferentiated CTB (Petroff et al. 2003).  A threshold level of B7-
H1 signaling within CTB co-cultures could be sufficient to drive Treg expansion and 
B7-H1 signaling effects may have reached a plateau within EGF-treated CTB co-
cultures, limiting further induction of Treg.   
In addition to B7-H1, both CTB and sTB express HLA-G and TGF-β which 
are also postulated to induce Treg expansion (Graham et al. 1992; Morales et al. 2003).  
Soluble HLA-G may mediate human bone marrow-derived mesenchmal stem cell 
induction of Treg (Selmani et al. 2008). However, other evidence suggests that this 
class Ib molecule does not induce CD4+CD25+FoxP3+ Treg (Bahri et al. 2006; Naji et 
al. 2007), and may instead preferentially induce other regulatory T cell subtypes with 
a CD3+CD4lo and CD3+ CD8lo phenotype (Le Rond et al. 2006; Naji et al. 2007).   
Thus,  direct testing of HLA-G within our culture conditions would be necessary to 
reconcile these data and determine its role in CTB-mediated Treg expansion.  The anti-
inflammatory cytokine TGF-β may also induce Treg differentiation from TCR 
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stimulated naïve CD4+ T cells, although this signal may require concomitant 
signaling through retinoic acid (Mucida et al. 2007).   
Trophoblast production of steroid hormones may also influence Treg 
expansion.  Estrogen treatment can cause Treg expansion in murine lymphoid organs 
and stimulate Treg proliferation in vitro; however it is unclear whether concomitant T 
cell receptor stimulation is required for these effects (Polanczyk et al. 2005; Prieto et 
al. 2006; Tai et al. 2008).   While estrogen is a possible candidate for trophoblast-
mediated Treg expansion within the placenta, it seems unlikely that it accounts for the 
effects we are observing in vitro, since both CTB and sTB lack the proper enzymes to 
independently synthesize estrogen (Pasqualini 2005).  Trophoblasts can 
autonomously convert cholesterol into progesterone (Pasqualini 2005), although the 
direct role of this hormone in Treg induction remains unclear.  In mice, exogenous 
delivery of progesterone either alone or in conjunction with estradiol did not cause 
expansion of Treg in secondary lymph organs (Zhao et al. 2007). However, 
progesterone causes promotion of a Th2 cytokine profile, some of which could favor 
Treg induction (Arck et al. 2007).    
As one or more of these trophoblast expressed molecules could be involved in 
Treg induction, further analysis utilizing various blocking reagents or recombinant 
proteins will be necessary to elucidate the molecular mechanisms at work within in 
our co-cultures.   In addition, it is unclear from the current results whether the 
trophoblast-mediated expansion of Treg is due to proliferation of a pre-cursor 
population or de novo differentiation. Although differentiation from naïve precursors 
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may be more likely scenario for human peripheral Treg in disease states (Pillai et al. 
2007), pregnancy-induced Treg expansion may be through different mechanisms. 
Indeed, first trimester trophoblast cells cause proliferation of a CD8+ regulatory T cell 
population (Shao et al. 2005).  
Whether through proliferation or differentiation, CTB-induced Treg expansion 
likely occurs in the absence of TCR stimulation, as MHC class II proteins are not 
expressed on human trophoblast cells (Murphy et al. 1998). While previous reports 
propose a requirement for TCR stimulation during central Treg induction (Jordan et al. 
2001; Apostolou et al. 2002; Hsieh et al. 2006), others suggest these cells may 
develop independently of MHC:TCR interactions (Haxhinasto et al. 2007). In 
addition, during murine pregnancy, peripheral Treg expand in females carrying either 
syngeneic and or semi-allogeneic fetuses, suggesting that Treg induction can occur 
through mechanisms independent of fetal antigen and TCR stimulation (Aluvihare et 
al. 2004).  However, Treg expressing the chemokine receptor CCR5, which have a 
stronger suppressive phenotype than CCR5- Treg, preferentially accumulate in the 
gravid uterus of allogeneic pregnancy.  Further, these cells exclusively confer 
maternal tolerance to semi-allogeneic fetuses (Kallikourdis et al. 2007). Thus, 
comparative analysis of the suppressive capabilities of Treg induced by CTB and those 
differentiated through other cellular interactions may be informative.  
These studies confirm the preferential localization of maternal Treg within 
decidual tissues and place trophoblast cells among the many factors that may 
influence Treg expansion.  In addition, our co-culture model provides a unique method 
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to study peripheral Treg induction in the absence of TCR:MHC interactions.  Finally, 
these results raise the interesting possibility that fetal tissues may influence Treg 
expansion during pregnancy as a means of self-protection against potentially harmful 
maternal immune activity.  
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Figure 3.1. Experimental model.  (A) Timeline for co-culture of undifferentiated 
and EGF-differentiated CTB:naïve T cell co-cultures. *, treatment with either 
medium or EGF.   (B) Schematic diagram of CTB and naïve CD4+ T cells co-culture.  
Scatter plot is representative of naïve CD4+ T cell purity as assessed through flow 
cytometry for CD4 and CD45 expression.  (C) Schematic diagram of assay to 
evaluate Treg suppression of autologous CFSE-labeled CD4+ proliferation following 
stimulation with anti CD3/CD28 plate-bound antibodies.   
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Figure 3.2.  Abundance of Treg in peripheral blood and decidual tissues at term 
pregnancy. Autologous peripheral blood and decidual lymphocytes were collected on 
the day of C-section followed by flow cytometric analysis.  (A) Representative dot 
plots of CD25 and FoxP3 expression on CD4+ lymphocytes.  (B) Graph represents 
summarized data from n=6 patients for the percentage of CD25+FoxP3+ cells out of 
CD4+ lymphocytes in each tissue.  Bars, SEM 
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Figure 3.3.  Term CTB induce expansion of Treg. Peripheral blood naïve CD4+ T 
cells were placed into culture for seven days with either untreated CTB 
(undifferentiated) or CTB treated for 96 hours with EGF prior to culture 
(differentiated).   EGF was maintained within medium of differentiated culture 
conditions throughout the incubation period.  (A) Representative dot plots of CD25 
and FoxP3 expression on CD4+ lymphocytes either before culture, or following 
culture with undifferentiated or EGF-treated CTB.  (B)  Graph represents summarized 
data for the percentage of of CD25highFoxP3+cells out of CD4+ lymphocytes from n=6 
different peripheral blood donors cultured with CTB from six different placentas.  
Bars, SEM.   Different letters indicate groups with significantly different values.  
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Figure 3.4.  Treg from CTB co-cultures suppress the proliferation of autologous 
activated CD4+ T cells.  CD4+CD25+ cells were isolated from co-cultures containing 
cytotrophoblast cells (CTB Treg) and placed into culture with CFSE-labeled 
autologous naïve CD4+ T cells (responders) stimulated with plate bound anti-CD3 
and anti-CD28 antibodies.  (A) Representative histograms of CFSE staining in 
unstimulated (unstim), and stimulated (stim) responder cells with or without CTB 
Treg.  Peaks labeled 0-5 correspond to the number of cell divisions with undivided 
cells designated as 0.  (B) Graph represents summarized data n=1 patient sample 
plated in duplicate.  Div, cell division. Bars, SEM. 
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A. Abstract 
The failure to reject the semiallogeneic fetus suggests that maternal T 
lymphocytes are regulated by potent mechanisms in pregnancy. The T cell 
immunoinhibitory receptor, Programmed Death-1 (PD-1), and its ligand, B7-H1, 
maintain peripheral tolerance by inhibiting activation of self-reactive lymphocytes.  
Here, we tested the role of the PD-1/B7-H1 pathway in maternal tolerance to the 
fetus. Antigen-specific maternal T cells both proliferate and upregulate PD-1 in vivo 
at mid-gestation in response to paternal antigen expressed by the fetus.  In addition, 
when these cells carry a null deletion of PD-1, they accumulate excessively in the 
uterus-draining lymph nodes (P < 0.001) without a concomitant increase in 
proliferation. In vitro assays showed that apoptosis of antigen-specific CD8+ PD-1-/- 
cells was reduced following peptide stimulation, suggesting that the accumulation of 
these cells in maternal lymph nodes is due to decreased cell death.  However, the 
absence of neither maternal PD-1 nor B7-H1 had detectable effects on birth rate, 
gestation length, litter size, or pup weight at birth in either syngeneic or allogeneic 
pregnancies. These results suggest that PD-1 plays a role in inducing apoptosis of 
paternal antigen-specific T cells during pregnancy, thereby controlling their 
abundance. 
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B. Introduction 
Over time, several mechanisms have evolved to ensure propagation of 
viviparous species, including transport of maternal nutrients to the developing fetus in 
utero.   A highly effective method for nutrient delivery is through hemochorial 
placentation in which maternal blood comes into direct contact with fetal trophoblast 
cells.  However, due to species genetic diversity, a paradox exists in which the mother 
must carry a fetus whose tissues are immunologically distinct from her own.   
Hemochorial placentation further complicates this paradox by allowing close 
juxtaposition of semi-allogeneic fetal tissues and the maternal leukocytes in the blood 
and uterine decidua.  
This type of placentation also enables access of fetal antigens to maternal 
secondary lymph organs through antigen shedding into the maternal blood space 
surrounding the villous placenta and trafficking to lymphoid organs via maternal 
antigen presenting cells (reviewed in Taglauer et al, submitted).  Indeed, fetal antigen 
can be detected in the maternal spleen and uterus-draining lymph nodes, and antigen-
specific T lymphocytes in both organs proliferate in response to fetal tissue during 
specific timepoints in gestation (Erlebacher et al. 2007).   The intimate contact of 
maternal and fetal tissues and maternal immune recognition of the fetus in secondary 
lymphoid organs would seem to pose an increased risk for immunological attack 
against the fetal allograft.  However, the reproductive and immune systems likely co-
evolved to develop immunosuppressive mechanisms within pregnancy to 
accommodate this situation, instead allowing the fetus to thrive.  
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Various immunomodulatory mechanisms are instrumental in controlling 
maternal leukocytes during pregnancy, including the B7 family of immune cell co-
stimulatory molecules (Petroff 2006a).  B7 molecules are cell surface proteins 
belonging to the immunoglobulin superfamily, and they bind to CD28 family 
receptors on leukocytes to influence their activation, either negatively or positively.  
One B7 family member, B7-H1, inhibits T lymphocyte activation through 
engagement of its receptor, PD-1 (Freeman et al. 2000; Latchman et al. 2001), and 
consequences of B7-H1:PD-1 interactions include suppression of proliferation, 
alteration of cytokines and induction of apoptosis (Freeman et al. 2000; Latchman et 
al. 2001; Hori et al. 2006; Muhlbauer et al. 2006; Keir et al. 2007; Zhang et al. 2008). 
PD-1 is expressed on activated lymphocytes in blood, lymphoid organs and tissues 
undergoing an immune response (Ishida et al. 1992; Agata et al. 1996).  
The suppressive action of PD-1 is demonstrated though in vivo studies in which 
targeted mutation or blockade of PD-1 results in spontaneous tissue-specific 
autoimmune disease (Nishimura et al. 1999; Nishimura et al. 2001) or T cell 
cytotoxicity against peripheral self-tissues (Martin-Orozco et al. 2006; Keir et al. 
2007).  This inhibitory receptor is also involved in preventing allograft rejection 
(Ozkaynak et al. 2002; Tanaka et al. 2007; Wang et al. 2007; Yang et al. 2008).   
Similarly, B7-H1-deficient mice are also more susceptible to experimentally induced 
autoimmune diseases (Dong et al. 2004; Latchman et al. 2004; Keir et al. 2006) and 
the absence of maternal B7-H1 may facilitate rejection of semi-allogeneic fetuses 
during pregnancy (Guleria et al. 2005; Habicht et al. 2007).  The B7-H1:PD-1 
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pathway thus appears to have a central function in maintaining immunological self-
tolerance in addition to tolerance to foreign grafts, including the fetal allograft.  
 
In this study we investigated the physiological function of maternal PD-1 and 
B7-H1 in pregnancy using murine T cell receptor transgenic and knockout models.   
Based on the published evidence for the central role of PD-1 in tolerance to self and 
foreign tissues, we hypothesized that this receptor has an important function in 
maternal tolerance of the fetal-allograft.  
 
C. Materials and methods 
Mice  
PD-1-/- and B7-H1 -/- mice on the C57BL/6 (B6) background were gifts from the 
laboratories of T. Honjo (Kyoto University) and L. Chen (Johns Hopkins University) 
(Nishimura et al. 1998; Dong et al. 2004) respectively. Wild type (WT) B6, BALB/c, 
CBA/J, B6-Tg(TcraTcrb)1100Mjb/J (OT-I), and B6-Tg(ACTB-OVA)916Jen/J (Ova-
Tg) mice were obtained from Jackson Laboratories (Bar Harbor, ME).     
All mice were housed under pathogen-free conditions.  For adoptive transfer 
experiments, PD-1+/- OT-I and PD-1-/-  OT-I mice were generated by crossing OT-I 
with PD-1-/- mice .   PD-1-/- and B7-H1-/- mice were genotyped using primers specific 
for PD-1 (Fwd: ACC AGG AAC TCC CCG TTA GT ; Rev: TAT TTA GGG TGC 
AGC CTC GT),  B7-H1 and neomycin (Dong et al. 2004), and  OT-I and OVA-Tg 
mice were genotyped using protocols from Jackson Laboratories.   Surface protein 
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phenotypes of PD-1-/- and B7-H1-/- mice were confirmed by stimulation of 
splenocytes with 3ug/mL conconavalin A (Sigma-Aldrich, St. Louis, MO) for 72h 
followed by flow cytometry. All experimental protocols were approved by the 
University of Kansas Medical Center Institutional Animal Care and Use Committee.    
 
Breeding experiments and assessment of fecundity  
To examine fecundity in the absence of maternal PD-1, virgin WT or PD-1-/- females 
were bred either syngeneically to B6 (H2b) males or allogeneically to BALB/c (H2d) 
males.  Similarly, virgin WT or B7-H1-/- female mice were mated syngeneically to B6 
(H2b) or allogeneically to CBA/J males to examine the role of maternal B7-H1 in 
pregnancy.  Vaginal plugs were evaluated each morning, and the presence of a 
vaginal plug was designated as gestation day (gd) 0.5.   Evaluation of fecundity 
included enumeration of healthy and resorbed implantation sites on gd 13.5, or 
examination of gestation length, litter size, pup weight at birth as well as pup weight 
and male/female ratios at weaning (postnatal day 21).   
 
Adoptive transfer 
For adoptive transfer experiments, virgin B6 female mice were bred to either B6 WT 
males (WT-bred) or OVA-Tg (OVA-bred) males. To obtain OT-I cells for adoptive 
transfer, splenocytes were isolated from virgin female WT OT-I or PD-1-/- OT-I mice 
and labeled with 5µM CFSE (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. OT-I surface phenotype was confirmed flow cytometry 
 98 
prior to transfer in all experiments. 10x106  CFSE-labeled splenocytes were 
transferred into WT- or OVA-bred recipient female mice on gd10.5 via injection into 
the tail vein.  Injection consistency was monitored by calculating the percentage of 
undivided (CFSEbright)  non-antigen-specific cells/total PALN lymphocytes, and did 
not differ significantly between experimental groups (P = 0.569, data not shown).   
On gd 13.5, PALN and spleen cells from recipient female mice were isolated and 
subjected to flow cytometric analysis.  
 
In vitro apoptosis and proliferation assays 
For analysis of activation-induced apoptosis and proliferation in vitro, splenocytes 
from virgin female WT OT-I or PD-1-/- OT-I mice were isolated and placed into 500 
µL total volume in a 24 well plate at density of 1 x 106 cells/well with either medium 
alone or 100ng/mL SIINFEKL peptide (ProImmune, Bradenton, FL).   For 
proliferation analysis, splenocytes were labeled with 5µM CFSE (Invitrogen) prior to 
culture. At 48 hours (apoptosis assay) or 72 hours (proliferation assay) following 
plating, cells were collected and analyzed by flow cytometry.  
 
Flow cytometry 
Isolated cells from spleen and/or lymph nodes were stained with the following anti-
mouse antibodies or reagents: CD8 phychoerythryn (PE)-Cy5 (clone H35-17.2, 
eBioscience, San Diego, CA), Vα2-PE (clone B20.1; BD Pharmingen, San Jose, CA), 
Vβ5-fluorescein isothiocyanate (FITC) (clone MH3-2; BD Pharmingen), PD-1-PE 
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(clone J43, eBioscience), B7-H1-PE (clone MIH5, eBioscience) and Annexin V-PE 
(BD Pharmingen). In all experiments, cells were labeled with LIVE/DEAD® Fixable 
Violet Dead Cell Stain Kit (Invitrogen).  A minimum of 500,000 lymphocytes for 
adoptive transfer experiments and 20,000 lymphocytes for in vitro 
apoptosis/proliferation assays were collected in a gate based on forward and side 
scatter characteristics. All samples were processed on a BD LSRII instrument and 
analyzed using BD FACSDiva™ (BD Pharmingen). 
 
Statistics 
Statistical significance was determined using Kruskal-Wallis one-way analysis of 
variance (ANOVA) on ranks for in vitro analysis of apoptosis, and one-way 
(ANOVA) for all other experiments. All pairwise multiple comparisons were 
performed with a Student-Newman-Keuls post-test.  Differences were considered 
significant at α = 0.05. 
 
D. Results 
PD-1 controls accumulation of paternal antigen-specific T cells during pregnancy.  
To determine whether PD-1 influences the fate of paternal antigen-specific T 
cells. we employed the OVA-OT-I model system, in which OT-I T cell receptor 
(TCR)-transgeneic T cells recognize the ovalbumin-derived SIINFEKL peptide. B6 
WT females were bred to either B6 WT or OVA-Tg males and CFSE-labeled OT-I 
splenocytes were adoptively transferred into pregnant females mid-gestation (gd 
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10.5). Three days post-transfer (gd 13.5), cells from uterus-draining lymph nodes and 
spleens were collected and stained for OT-I T cell receptor markers and PD-1 and 
analyzed by flow cytometry (Fig. 4.1).  In the PALN of females mated to WT males, 
OT-I cells were rare and did not proliferate (Fig. 4.1a). In contrast, in the PALN of 
OVA-Tg-mated females, OT-I cells were readily detected and showed significantly 
higher percentage of proliferating cells (OVA-Tg bred vs WT-bred, P < 0.01) while 
non-antigen specific spleen cells did not proliferate (Fig. 4.1b). In addition, 
proliferating paternal antigen-specific CD8+ T cells expressed the PD-1 receptor (Fig. 
4.1 c).  Similar proliferation and PD-1 expression on OT-I cells was observed within 
the spleens of Ova-Tg mated females (data not shown).   
We next examined the effect of PD-1 deficiency during paternal antigen-
specific T cell responses by transferring either WT OT-I or PD-1-/- OT-I CFSE-
labeled cells into virgin, WT-bred, or OVA-bred female recipients.   In the PALN of 
Ova-Tg bred females, paternal-antigen specific T cells lacking PD-1 were more 
abundant than WT OT-I cells (Fig. 4.2 a), relative to both total lymphocytes (P < 
0.001, Fig. 4.2 b) and CD8+ T cells (P <0.001, Fig. 4.2 c).  This difference was not 
observed in WT-bred recipients, as the abundance of both WT-OT-I and PD-1-/- OT-I 
cells in these mice was similar to virgin females (Fig. 4.2 b,c).  Conversely, in the 
spleens of OVA-Tg bred females, OT-I T cells accumulated regardless of PD-1 
expression, particularly relative to endogenous splenic CD8+ T cells (Fig. 4.2 e-g).  
However, no significant differences in the number of fetal resorption sites in females 
receiving OT-I WT or OT-I PD-1-/- cells were observed (data not shown).    
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To determine a potential mechanism for paternal antigen-specific T cell 
accumulation in the absence of PD-1, we evaluated the proliferation of adoptively 
transferred cells at gd 13.5.  There was no alteration in the percentage of dividing WT 
OT-I or PD-1-/- OT-I cells in the PALN or spleen of OVA-Tg bred females (Fig 4.2 
d,h), suggesting that accumulation was not due to increased proliferation by PD-1-
deficient cells.  We next examined the possibility that PD-1 limits accumulation of 
paternal antigen-specific T cells through induction of apoptosis. WT OT-I or PD-1-/- 
OT-I splenocytes were stimulated in vitro with SIINFEKL peptide followed by 
examination of proliferation and apoptosis using flow cytometry. CFSE-labeled OT-I 
cells stimulated with SIINFEKL peptide showed no significant difference in 
proliferation between WT and PD-1-/- cells (Fig. 4.3 a,b), consistent with our 
observations in vivo (Fig. 4.2 d,h).  In parallel experiments, decreased percentages of 
peptide-stimulated PD-1-/- OT-I cells were positive for Annexin V as compared to 
WT OT-I cells (Fig. 4.3 c,d), suggesting that PD-1 deficient cells are less susceptible 
to activation induced cell death.  
 
PD-1 is not required for fetal survival during allogeneic pregnancy 
Because PD-1 controls the accumulation of paternal antigen-specific T cells, 
we next examined whether maternal PD-1 is required for tolerance to the semi-
allogeneic fetus.   C57BL/6 WT and PD-1-/- females were mated with either B6WT or 
BALB/c males followed by evaluation of birth rate, gestation length, litter size, and 
offspring neonatal and weaning weights. The absence of PD-1 in PD-1-/- mice was 
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confirmed through flow cytometry (Fig. 4a).   No significant alteration in the birthrate 
or other gestational or neonatal offspring parameters was observed between syngeneic 
and allogeneic pregnancies in WT and PD-1-/- mice  (Fig. 4.4 b-e).  Also, there was 
no consistent trend in the ratios male and female offspring among the breeding groups 
examined (data not shown); however weight was increased in offspring born from 
PD-1-/- mothers, an effect seen in both syngeneic and semi-allogeneic litters (Fig. 4.4 
f).  
These results were unexpected, given a previous report that maternal tolerance 
of semi-allogenic fetuses is dependent on the PD-1 ligand, B7-H1 (Guleria et al. 
2005).  We therefore re-examined whether B7-H1 was critical for the success of 
allogeneic pregnancy by evaluating the fecundity of female B7-H1-/- mice during 
syngeneic and allogeneic pregnancy (Fig. 4.5). Our results from the B7-H1-/- female 
syngeneic or allogeneic crosses were consistent with those observed for PD-1-/- mice, 
with no obvious changes in gestation rate or offspring viability (Fig. 4.5 b-f). Overall, 
these data strongly suggest that neither maternal PD-1 nor B7-H1 are required for the 
viability of semi-allogeneic fetuses.  
 
E. Discussion 
The overall goal of these studies was to examine the role of the B7-H1:PD-1 
pathway in maternal-fetal tolerance.   To address this question, we utilized PD-1-/- and 
B7-H1-/- mice as well as adoptive transfer of T cells specific for paternal antigen. We 
found that PD-1 control the accumulation of paternal antigen-specific CD8+ T cells in 
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the PALN possibly through induction of apoptosis.  However, there was no effect on 
the fecundity or offspring survival during allogeneic pregnancy in the absence of 
either maternal PD-1 or B7-H1. 
We investigated the role of PD-1 on T cells in pregnancy using an approach 
that enables analysis of paternal antigen-specific responses at the cellular level.  By 
adoptively transferring OT-I cells into WT females bred to Ova-Tg males, we found 
that OT-I cells specific for paternal ovalbumin express PD-1 (Fig. 4.1).  Further, OT-I 
T cells accumulated to a greater extent in the PALN of OVA-bred females only in the 
absence of PD-1 (Fig. 4.2 a-d), whereas in the spleen OT-I cells accumulated 
regardless of PD-1 expression (Fig. 4.2 e-h).  A previous study showed that during 
pregnancy, adoptively transferred paternal antigen-specific T cells do not accumulate 
despite high proliferation in the PALN and spleen, suggesting that these cells are 
being deleted (Erlebacher et al. 2007).  These results are similar to our observations 
for WT OT-I cells in the PALN (Fig. 4.4).  However, accumulation did occur in 
absence of PD-1, suggesting that this receptor may be involved in the deletion of the 
paternal-antigen specific T cells.  We did not observe decreased accumulation of WT 
OT-I cells in the spleen by three days post adoptive transfer, suggesting that the 
kinetics of paternal antigen-specific T cell deletion may differ between the PALN and 
spleen.   
Other reports also propose that paternal antigen specific T cells are deleted 
within maternal lympohoid organs.  CD8+ T cells specific for the paternal antigen H-Y 
undergo an expansion in both the PALN and spleen during early-mid gestation 
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followed by a contraction in numbers that continues until term (Vacchio et al. 1999).  
The interactions of CD28/B7 or Fas/FasL may facilitate deletion of these cells in the 
spleen during late gestation (Vacchio et al. 2003; Vacchio et al. 2005).  While these 
studies examined endogenous, rather than adoptively transferred, maternal T cells, the 
current study suggests that PD-1 may be an additional mechanism for controlling 
accumulation of paternal antigen-specific T cells within the lymph nodes draining the 
gravid uterus.  Continued analysis of these models using mice lacking PD-1 along 
with Fas/FasL and/or the CD28/B7 proteins would provide insight into whether these 
pathways work in conjunction to prevent propagation of maternal effector T cell 
activity during pregnancy.    
The effects of PD-1 on OT-I T cells during pregnancy are congruent with 
previous models where a lack of PD-1 on adopively transferred OT-I cells caused an 
increased accumulation of these cells in draining lymph nodes of peripheral tissues 
expressing ovalbumin (Martin-Orozco et al. 2006; Keir et al. 2007). The eventual 
result of this accumulation was an antigen-specific attack against self-tissues.  In our 
model we did not see an increase in fetal resorption sites following injection of      
PD-1-/- fetal antigen-specific T cells (data not shown).  In these previous studies, the 
earliest signs of tissue destruction were not evident until approximately 5 days post 
injection, so the lack of effect on fetal viability seen in our model could be due to 
insufficient duration of antigenic exposure in vivo, as we examined implantation sites 
only 3 days following transfer of OT-I cells.  More likely, however, is that fetal loss 
by these cells would not occur, given the results of PD-1-/- female allogeneic 
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pregnancies and apparent redundancy of immunosuppressive mechanisms at the 
maternal-fetal interface (Fig. 4.4) (Petroff 2005a).  
The B7-H1:PD-1 pathway can inhibit T lymphocytes through several 
mechanisms including control of proliferation, alteration of cytokine production and 
induction of apoptosis (Freeman et al. 2000; Latchman et al. 2001; Hori et al. 2006; 
Muhlbauer et al. 2006; Keir et al. 2007; Zhang et al. 2008).   Our results support a role 
for PD-1 in apoptosis of paternal antigen-specific T cells rather than inhibition of 
proliferation (Fig. 4.2, 4.3).  Indeed, the downstream inhibitory effector of PD-1 
signaling, SHP-2 phosphatase  participates in apoptosis induction and following 
ligation of PD-1, one net effect of SHP-2 recruitment is downregulation of PI3K and 
ERK anti-apoptotic pathways (Ballif et al. 2001; Okazaki 2001; Yuan et al. 2005).   In 
addition, PD-1 signaling with concomitant T cell receptor stimulation prevents 
upregulation of the prosurvival molecule Bcl-2 (Keir et al. 2005).  Interestingly, an 
overexpression of Bcl-2 causes increased accumulation and reduced apoptosis of 
antigen-specific T cells in tissue-draining lymph nodes (Redmond et al. 2008).   In the 
current study, a lack of PD-1 did not alter the proliferation of OT-I cells either in vivo 
(Fig. 4.2 d,h) or in vitro (Fig. 4.3 a,b).  However, in the absence of PD-1, a lower 
percentage of in vitro peptide-stimulated OT-I cells were apoptotic (Fig. 4.3 c,d), 
which parallels the effects of Bcl-2 overexpression.  These results point to a role for 
PD-1 in controlling accumulation of fetus-specific T cells in uterus-draining lymph 
nodes through induction of apoptosis, which may be mediated by downregulation of 
Bcl-2. 
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Several studies have shown that PD-1 is involved in maintaining tolerance to 
both self and allograft tissues (Martin-Orozco et al. 2006; Keir et al. 2007; Tanaka et 
al. 2007; Wang et al. 2007).   However, the lack of fetal rejection at term pregnancy 
in PD-1-/- mothers indicates that fetal allograft viability is not dependent on PD-1: B7-
H1 interactions (Fig. 4.4). Our results conflict with a previous report in which B7-H1-
/- mothers lose tolerance to semi-allogeneic fetuses (Guleria et al. 2005).   The 
inhibitory effects of B7-H1 may be propagated through a receptor other than PD-1 
(Dong et al. 2002) , which could reconcile our divergent observations for the PD-1-/- 
mice. However, we also examined the fecundity of B7-H1 deficient females 
following syngeneic and allogeneic breeding and found no significant differences in 
the gestation rate or offspring viability between B6WT and B7-H1-/- mice  (Fig. 4.5). 
The discrepant results between the current and previous analyses of B7-H1 functions 
during pregnancy draws attention to the differences between the B7-H1-/- mice 
utilized for each study.  The B7-H1-deficient mice in the previous study lack exons 2 
and 3 of the B7-H1 gene, which differs from the mice used in the current study which 
lack exon 1 and majority of exon 2 (Dong et al. 2004).  However, both of these 
strategies delete the exon 2-encoded PD-1 binding site from the B7-H1 transcript 
(Wang et al. 2003; Dong et al. 2004; Guleria et al. 2005).  In addition, the mice in our 
study lack the leader sequence for B7-H1 (exon 1), precluding B7-H1 from being 
expressed on the surface of lymphocytes, as confirmed by flow cytometry (Fig. 4.5).   
However, as the variation in B7-H1 deletion constructs are the main identifiable 
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difference between these two reports, the specific mechanism(s) for the divergent 
results from these two studies remains unclear.    
While the absence of maternal PD-1 did not affect fetal survival, offspring 
were significantly heavier at the time of weaning. This effect was seen in both 
syngeneic and allogeneic pregnancies and may be due to an altered immunologic 
environment during pregnancy or changes in lactation physiology. PD-1 is known to 
inhibit pro-inflammatory cytokine production (Freeman et al. 2000; Latchman et al. 
2001; Keir et al. 2007), and thus in the absence of PD-1 during pregnancy could 
propagate an inflammatory environment that may influence body composition later in 
life. A similar effect was also be observed in mice lacking the anti-inflammatory 
cytokine IL-10, where fetuses from IL-10 deficient mothers were heavier at birth 
(White et al. 2004) and recent evidence suggests that obesity in both children and 
adults can be associated with altered physiology caused by inflammatory processes 
(Das 2001).   In addition, while the role of PD-1 in lactation physiology remains 
unclear, PD-1 may be involved in homeostatic immune processes during lactation that 
could have downstream effects on offspring growth.   
Overall, these results strongly suggest that neither maternal PD-1 nor its 
ligand B7-H1 are indispensable for fetal survival during allogeneic murine 
pregnancy.  The current study is consistent with several previous reports in which 
abrogation of an immunoinhibitory mechanism during pregnancy does not affect 
survival of the semi-allogeneic fetus (Petroff 2005a).   During pregnancy, 
inflammatory signals are absent during presentation of fetal antigen to maternal T 
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cells, which could be a broad-spectrum mechanism to ensure maternal-fetal tolerance 
(Bonney et al. 1998). However, rejection of semi-allogenic fetuses can occur in the 
absence of regulatory T cells or galectin-1 (Aluvihare et al. 2004; Darrasse-Jeze et al. 
2006; Blois et al. 2007), suggesting that tolerance is more than the paucity of 
maternal immune reactivity simply due to the absence of a danger signal. Further, a 
functional hierarchy may exist among the network of immunomodulatory pathways 
present at the maternal-fetal interface.   Within this network, the B7-H1:PD-1 
pathway may modulate the accumulation of paternal antigen-specific T cells in the 
uterus draining lymph nodes through a mechanism involving apoptosis and operate in 
conjunction with other immunotolerizing mechanisms for the ultimate goal of 
maintaining healthy gestation and fetal development.   
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Figure 4.1. Paternal antigen-specific T cells proliferate and express PD-1 during 
pregnancy. CFSE-labeled spleen cells from OT-I mice were transferred at gd 10.5 
into females bred to ova-transgenic (OVA) or WT males.  On gd 13.5, cells from the 
peri-aortic lymph nodes were stained for OT-I markers and PD-1 and analyzed by 
flow cytometry.  (a,b) Representative dot plots and histograms of  CD8+/Va2+ OT-I 
cells in the peri-aortic lymph nodes of either WT (a) or OVA bred females (b).  (c) 
Representative dot plot and histogram of PD-1 expression in maternal OT-I cells in 
the peri-aortic lymph nodes.  Empty peak, isotype control. MFI, mean fluorescence 
intensity. Figure representative of n=4 female recipients.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 111 
 
 
 
 
 
 
 
 112 
Figure 4.2. PD-1 controls accumulation of paternal antigen-specific T cells in the 
uterus draining lymph nodes. CFSE labeled splenocytes from WT or PD-1-/- mice 
were adoptively transferred into virgin, WT-bred or OVA-bred females on gd 10.5.  
Recipient female peri-aortic lymph nodes and spleens were collected on gd 13.5 and 
analyzed by flow cytometry. (a,e)  Representative dot plots of  peri-aortic lymph node 
(a) and spleen (e) cells stained for CD8 and Vα2.  (b,f)  Graph represents percentage 
of OT-I cells out of total peri-aortic (b) or splenic (f) lymphocytes in virgin (n =3), 
WT bred (n = 3) or OVA bred (n = 4) females. (c,g) Graph represents percentage of 
OT-I cells out of peri-aortic (c) or splenic (g) CD8+ cells in same groups as described 
for b and f. (d,h) Graph represents the percentage of OT-I (CD8+Vα2+) cells in the 
peri-aotric lymph nodes (d) or spleen (h) undergoing more than 3 cell divisions. 
Different letters denote groups whose difference was statistically significant. 
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Figure 4.3. PD-1 induces apoptosis without altering proliferation in activated 
antigen-specific T cells. Unlabeled (a,b) or CFSE-labeled (c,d) OT-I WT and PD-1-/- 
splenocytes were placed into culture with 100ng/mL SIINFEKL peptide or medium at 
37o C for a total of 72 hours followed by flow cytometric analysis for OT-I markers 
(CD8, Vα2) and/or apoptosis markers (Annexin V, Violet Live/Dead Stain).  (a) 
Representative dot plots of CD8+ Va2+ splenocytes analyzed for apoptosis markers 
following 48 hour culture.  Lines were set based on unstained cells for Violet 
Live/Dead stain and fluorescence minus one controls for Annexin V stain.  (b) Graph 
represents summarized data from n=4 mice/group. Different letters denote groups 
whose difference was statistically significant.  (c) Representative dot plots of CFSE-
labled CD8+ Va2+ splenocytes splenocytes analyzed for proliferation following 72 
hour culture.  (d) Graph represents summarized data from n=4 mice/group. 
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Figure 4.4.  PD-1 is not required for the maintenance of allogeneic pregnancy. (a) 
Whole splenocytes were stimulated with conconavalin A for 72 hours at 37oC 
followed by flow cytometric analysis of PD-1.  Empty peaks, isotype control.  (b) 
analysis of gestation rate for syngeneic (syn) and allogeneic (allo) matings in WT 
(syn: n=12, allo: n=10) and PD-1-/- (syn: n=8, allo: n=10); (c-e) analysis of gestation 
length (c), litter size (d), and fetal weight at birth (e)/weaning (f) in syngeneic (syn) 
and allogeneic (allo) pregnancies in WT (syn: n=9, allo: n=7) and PD-1-/- (syn: n=5, 
allo: n=5) females. Different letters denote groups whose difference was statistically 
significant. 
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Figure 4.5. B7-H1 is not required for the survival of allogeneic fetuses. (a) Whole 
splenocytes were stimulated with conconavalin A for 72 hours at 37oC followed by 
flow cytometric analysis of B7-H1. Empty peaks, isotype control.  (b-f) Analysis of 
gestation rate (b), gestation length (c), litter size (d), and fetal weight at birth 
(e)/weaning (f) in syngeneic (syn) and allogeneic (allo) pregnancies in WT (syn: n=9, 
allo: n=4) and PD-1-/- (syn: n=5, allo: n =5) females.  No values were significantly 
different in any of the graphs displayed.   
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Taglauer, E.S., Adams Waldorf, K.M., Petroff, M.G., The hidden maternal-fetal 
interface: secondary lymphoid organs and maternal-fetal tolerance. (Submitted)    
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A. Conclusions  
The overall objective of these studies was to add to the existing knowledge 
about maternal T cell regulation during pregnancy.  More specifically, we examined 
the expression and function the immunoinhibitory receptor PD-1 within multiple sites 
of the maternal-fetal interface.  First we found that the abundance of PD-1- 
expressing cells increases dramatically within human decidual tissues throughout 
gestation as compared to non-pregnant endometrium. We then identified that PD-1 is 
preferentially expressed on maternal T cell subpopulations in the term decidua and 
that B7-H1 modifies the cytokine repertoire of decidual T cells  (Fig. 5.1 A).   Next 
we established that human trophoblast cells induce expansion of regulatory T cells 
(Fig 5.1 B).  Finally we found that PD-1 is required for deletion of paternal antigen-
specific T cells in the uterus-draining lymph nodes during pregnancy (Fig 5.1 C). 
These results identify novel functions of the B7-H1:PD-1 pathway in maternal-fetal 
tolerance and highlight the importance of examining multiple sites of immune 
regulation during pregnancy. 
Throughout gestation there are numerous sites of interaction between the 
maternal immune system and fetal tissues (reviewed,Taglauer et al, submitted).  One 
site is between maternal leukocytes in the decidua and blood surrounding the fetal 
placenta and membranes (Fig 5.1 A.B).  Another less well-characterized interface is 
within the secondary lymph nodes in pregnant females (Fig 5.1 C).   Our studies 
suggest that the B7-H1:PD-1 pathway regulates maternal T cells within both of these 
interfaces, but through distinct mechanisms.  B7-H1 modifies cytokine production 
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without induction of cell death of decidual CD4+ T cells (Fig. 5.1 A).  
Cytotrophoblast cells are capable of inducing Treg expansion in vitro which may 
involve pathways including B7-H1 signaling (Fig. 5.1 B).  Finally within the uterus-
draining lymph nodes, PD-1 limits accumulation of proliferating CD8+ T cells 
potentially through induction of apoptosis (Fig. 5.1 C). The diverse outcomes of B7-
H1:PD-1 interactions within these different models reflects the diverse repertoire of  
inhibitory mechanisms utilized by this pathway in order to suppress T lymphocytes 
(Freeman et al. 2000; Latchman et al. 2001; Hori et al. 2006; Muhlbauer et al. 2006; 
Keir et al. 2007; Zhang et al. 2008).  Indeed, following PD-1 ligation, the SHP-2 
phosphatase acts on numerous target proteins involved in diverse signaling pathways, 
congruent with multiple outcomes following B7-H1:PD-1 ligation (Okazaki 2001).   
We propose that the varied consequences of B7-H1:PD-1 interactions 
observed in these studies may function together to create multiple checkpoints for 
maternal T cell control.  During pregnancy, fetal antigen traffics to the lymph node 
and where it is presented to T cells by maternal APC (Erlebacher et al. 2007). The T 
cells subsequently respond by proliferating and upregulating activation markers 
(Erlebacher et al. 2007).  PD-1 is also upregulated during this proliferation and upon 
ligation of B7-H1, its signaling may alter prosurvival/proapoptotic pathways to 
induce apoptosis of fetal-antigen specific cytotoxic CD8+ T cells thereby preventing 
their accumulation (Fig. 5.1 C).  Our finding that abrogation of this signal alone does 
not result in immunological attack of fetal tissues suggests that PD-1 works in 
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conjunction with other suppressive mechanisms to preclude perpetuation of maternal 
CD8+ T cell effector functions.   
In addition to their responses within the uterus-draining lymph nodes, it is 
clear that some maternal T lymphocytes populate to the uterus following implantation 
and once there, are not entirely quiescent, as evidenced by their expression of 
activation markers (Chao et al. 1999).   Our studies suggest that B7-H1 on trophoblast 
cells interacts with PD-1 on decidual T cells to selectively modify their cytokine 
production, without induction of apoptosis, thereby allowing decidual T cells to carry 
out potential physiological functions in a controlled manner (Fig. 5.1A).  Indeed, an 
excess of activated decidual T cells appears to be associated with a pathologic 
outcome of pregnancy, such as recurrent spontaneous abortion (Maruyama et al. 
1992; Vassiliadou et al. 1999; Quack et al. 2001).  Treg expanded by placental 
trophoblasts or other mechanisms (Polanczyk et al. 2005; Blois et al. 2007; 
Kallikourdis et al. 2007) may control proliferation of maternal T cells to regulate their 
abundance within the decidua (Fig. 5.1B).   
This multi-site activity is reflective of how the B7-H1:PD-1 pathway 
functions to maintain self-tolerance to peripheral tissues.  For example, modulation of 
antigen-specific responses against pancreatic tissues involves B7-H1:PD-1 regulation 
within both draining lymph nodes and parenchymal tissue cells (Keir et al. 2007).   
Similar to our observations in murine pregnancy, PD-1 suppresses antigen-specific T 
cell activation in the pancreatic-draining lymph nodes. In addition, B7-H1-expressing 
pancreatic islet β cells islet cells provide an additional source of T cell modulation, 
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analogous to the functions we propose for B7-H1 expressing trophoblast cells in the 
human placenta.    
Self-tolerance has been described as “a robust state with multiple checkpoints 
that must be overcome before autoimmunity is unleashed” (Hamilton-Williams et al. 
2005).   The same can be said of tolerance to fetal antigens in pregnancy; indeed, 
dependence on a single tolerizing mechanism could be catastrophic for species 
propagation. These studies suggest that B7-H1:PD-1 interactions control maternal T 
lymphocyte activity at multiple sites through diverse mechanisms. In light of the 
current results, future analysis of suppressive pathways in pregnancy should consider 
their activity within multiple sites of interaction between maternal immune cells and 
fetal cells/antigens.  
 
B. Future Directions 
The immune system is composed of several cell types functioning through 
complex series of signals and cellular interactions. Thus, examination of individual 
leukocyte populations must be followed with an analysis of their interactions with 
other components of the immune system.   Several studies to date have focused on 
maternal T cell activation and effector function in response to both major and minor 
fetal antigens, and several lines of evidence point to a hyporesponsiveness of these 
cells.  However, a critical component of peripheral tolerance is not only the resulting 
anergy or deletion of T cells, but also the status of the dendritic cell (DC) delivering 
the antigen against which that T cell must be tolerized. A valuable, yet understudied, 
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area of research of maternal-fetal tolerance is examination of maternal antigen 
presenting cells within secondary lymphoid organs during pregnancy. Indeed, DC 
within lymph nodes draining mucosal immune sites have different, and often uniquely 
tolerogenic properties compared to systemic lymph nodes (Kraal et al. 2006).      
Local microenvironments play an important role in dictating dendritic cell 
function and phenotype.  Pregnancy itself may alter specific properties of dendritic 
cells within decidua or other tissues through mechanisms including hormones, 
cytokines, and HLA-G (Steinbrink et al. 2000; Holmes et al. 2003; Seavey et al. 
2006; Apps et al. 2007).  In addition, DC may also be programmed through ingestion 
and presentation of foreign antigens associated with dying cells, known mechanism to 
induce long-lasting T cell tolerance provided that inflammatory signals are absent 
(Liu et al. 2002). Apoptotic trophoblast cells and debris containing fetal antigens are 
regularly shed into the maternal circulation during pregnancy, providing exactly the 
right types of signals to immature maternal dendritic cells for induction of T cell 
tolerance.  
Thus presentation of fetal antigens by maternal DC could be a means to 
educate the maternal immune system to prevent anti-fetal reactions (Blois et al. 
2007).   This may be in contrast to pathological pregnancies in which overabundance 
or imbalance of immunogenic dendritic cells might lead to failure of immunological 
tolerance of the fetus (Askelund et al. 2004; Huang et al. 2008).  Additionally, 
maternal DC presentation of fetal-derived peptides may change maternal 
immunologic “self” temporarily during pregnancy (Adams et al. 2007). In fact, co-
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presentation of fetal and maternal peptides could lead to transient remission of certain 
autoimmune diseases during pregnancy (Hench 1938; Kung et al. 1998; Houtchens 
2007).  Thus, further studies of DC in maternal-fetal tolerance may have broader 
applications and could provide compelling models for the study of autoimmunity.  
 
C. Overall Significance 
  These studies have mapped expression of PD-1 during pregnancy and defined 
its role in modifying maternal T lymphocyte activity. Improper control of maternal T 
lymphocyte activation is associated with recurrent spontaneous abortion and pre-
eclampsia in humans (Maruyama et al. 1992; Piccinni et al. 1998; Vassiliadou et al. 
1999; Quack et al. 2001; Sasaki et al. 2004; Darmochwal-Kolarz et al. 2007; Sasaki et 
al. 2007; Yang et al. 2007) and allogeneic fetal loss in mice (Aluvihare et al. 2004; 
Darrasse-Jeze et al. 2006).  Thus, the conclusions drawn from our work may begin to 
provide a basis for novel therapies in these pregnancy pathologies. The B7-H1:PD-1 
pathway is also involved in self-tolerance, allograft acceptance, and cancer.  
Understanding how B7-H1 and PD-1 are naturally recruited during pregnancy to 
control maternal immune activity may aid in the development of improved treatments 
for autoimmune disease and transplantation and more effective models for targeting 
tumor growth.  
This research also gives insight into the mechanisms through which the 
adaptive immune system is properly controlled despite its broad spectrum of 
functions throughout the body.  Because its activity involves several cells and signals 
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located within numerous tissues, modulation of adaptive immunity may employ a 
specific repertoire of mechanisms with diverse applications at multiple sites, as we 
have observed for the B7-H1:PD-1 pathway in pregnancy.   Further, our work 
highlights that the designation of “adaptive” for this branch of the immune system 
means that it not only adapts to mount specific responses against pathogens, but also 
can be adapted through immunosuppressive pathways to accommodate physiological 
events that are beneficial for propagation of the species.     
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D. Figures and Legends 
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Figure 5.1 Functions of PD-1 within the multi-faceted maternal-fetal interface. 
Schematic diagrams showing immunomodulation through PD-1:B7-H1 interactions 
within the placenta (A,B) and uterus draining lymph nodes (C).  (A)  PD-1 expressed 
on decidual T cells may interact with B7-H1 on trophoblast cells  interactions within 
extraplacental membranes to modify their cytokine production.   (B)  Cytotrophoblast 
cells in the villous placenta induce regulatory T cells (Treg)  (C) B7-H1:PD-1 
interactions within the peri-aortic lymph nodes may control accumulation of paternal 
antigen-specific T cells during pregnancy through induction of apoptosis.  
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